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Abstract 
John M Kinzfogl 
NEUREXOPHILIN1 SUPRESSES THE PROLIFERATION  
OF HEMATOPOIETIC PROGENITOR CELLS 
Neurexin I alpha (NRXN1α) and Dystroglycan (DAG1) are membrane receptors which 
serve as mutual ligands in the neuronal system.  Neurexophilins (NXPHs) bind NRXN1α.  
Both NRXN1α and DAG1 were expressed in primitive populations in human cord blood 
(huCB) and murine bone marrow (muBM), with high concentrations of NXPHs in huCB 
plasma.  We evaluated effects of these molecules on huCB and muBM hematopoietic 
progenitor (HPC) and stem (HSC) cells.  At both a single and population level in vitro, we 
found that NXPH1 is a potent inhibitor of HPC proliferation acting through NRXN1α, an 
effect antagonized by DAG1.  Injection of recombinant NXPH1 in vivo resulted in myelo- 
and lymphosuppression, with absolute numbers and cycling status of functional and 
phenotypically defined HPCs dose- and time-dependently decreased, and absolute 
numbers and cycling status of phenotypically defined longer-term repopulation HSCs 
increased.  Competitive transplants showed an initial decrease in engraftment of 
NXPH1-treated cells, with an intermediate stage increase in engraftment.  The increase 
in HSCs is at least partially mediated by the mTOR pathway and is thought to be 
homeostatic in nature.  These results demonstrate the presence and function of a 
regulated signaling axis in hematopoiesis centered on NRXN1α and its modulation by 
DAG1 and NXPH1.  
Hal E. Broxmeyer, Ph.D., Chair 
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Introduction 
 
Historical overview 
 
In the study of human physiology, blood has always maintained an esteemed position.  
Hippocrates listed blood as one of the four humors that creates the body.  The sanguine 
humor was associated with a passionate and courageous, if flighty, temperament.  The 
first recognizable medical investigation of blood was performed by Galen (131-201CE), 
the most influential physician in history.  He discovered that blood was carried by the 
arteries and, combining the philosophy of Hippocrates with observations from dissected 
animals, hypothesized that the liver was the hematogenic organ, where hematopoiesis 
begins (Boylan 2007). 
 
These philosophies of blood existed with little challenge until the Scientific Revolution.  
Blood cells were first observed in 1658 by Jan Swammerdam, though formal study of 
blood cells did not begin until 1674 with Anton van Leeuwenhoek’s work.  Despite these 
early discoveries, it would take over a century before components of blood other than 
red cells were discovered.  As part of his work with the vaginal secretions of prostitutes, 
Alfred Donné would discover platelets in 1842.  White blood cells were simultaneously 
identified in 1843 by Gabriel Andral in France and William Addison in England.  After the 
discovery of the three main elements of blood, Lionel Beale and others attempted to 
further characterize them using microscopy.  This approach met with little success until 
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1879 when Paul Ehrlich published his techniques for staining blood films and differential 
blood counting (Hajdu 2002). 
 
The science of blood transfusions progressed in a similar manner, with a strong early 
start at around the same time blood was first described, coupled with a combination of 
scientific and cultural road-blocks that slowed its development.  The first recorded 
successful blood transfusion was performed by Richard Lower on dogs in 1665.  After 
initial experiments, Lower found that stitching the artery of the donor animal to the vein 
of the recipient was the most favorable combination, so a medium sized dog was bled 
from the jugular vein until it was close to death.  Using a reed, he then connected a neck 
artery of a large dog to the jugular of the bled animal.  He allowed blood to flow into the 
recipient until the donor died.  As if by magic, the smaller dog seemed to come back 
from the dead and after the jugular vein was sewed close it leapt from the table and 
rolled in the grass to clean itself from the blood as though nothing had happened 
(Keynes 2010).   
 
This work would be expanded upon by Jean-Baptiste Denis, who in 1667 performed the 
first blood transfusion in a human being using calf’s blood.  The recipient, Antoine 
Mauroy, was a madman who suffered from violent outbursts and it was thought that 
the gentle nature of the calf would temper his condition.  Antoine Mauroy not only 
survived the experience but it also seemed to treat his condition: his violent outbursts 
subsided and the evil which had driven him mad was expelled as black urine.  The black 
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urine is immediately recognizable to modern scientists as a result of hemolysis.  The 
human immune system recognized the calf’s blood as foreign and destroyed them, 
thereby releasing hemoglobin into the bloodstream.  However, that his madness was 
actually treated by the procedure is at first quite surprising though knowledge of the 
source of Mauroy’s madness clarifies this issue somewhat.  A regular patron of brothels, 
it is probable that Mauroy’s violent outbursts stemmed from syphilis.  Treponema 
pallidum has a poor tolerance for elevated temperatures and the fever caused by the 
xenotransfusion likely killed the bacteria (Starr 2000). 
 
The publication of Denis’ experiment would create a fad of blood transfusion 
throughout Europe.  While the initial success of cross-species transfusions may be 
surprising to modern readers, the eventual deaths resulting from it are not.  In 1670 the 
French Parliament banned all transfusions involving humans, a move quickly followed in 
England and Rome.  It would be over 100 years before blood transfusion was once again 
visited by scientists (Ficarra 1942).  In 1795 the first human-to-human blood transfusion 
is thought to have been performed by Philip Syng Physick in Philadelphia, though the 
first published account was performed by James Blundell in 1818 (Rudmann 2005).   
 
Following the work of Blundell, transfusions during the 19th century relied on surgically 
connecting the artery of the donor with the vein of the recipient.  Because of the high 
mortality associated with transfusions, this procedure remained relatively rare.  The first 
problem inherent to blood transfusion is blood type – a problem that would persist until 
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1901 with Karl Landsteiner’s characterization of blood types (Society, Hankins et al. 
2001).  The second problem was the actual method of transfusion.  Echoing the 
experiments of Lower two centuries prior, transfusion in the 19th century required a deft 
surgeon who could both attach the artery and vein of the donor and recipient as well as 
detach and close each without killing either the donor or the recipient.  This technique 
was simplified by Dr. Aveling who developed an apparatus consisting of two silver tubes 
connected by a length of rubber tubing with a squeeze bulb attached (Aveling 1872).  No 
longer the provenance of highly specialized individuals, transfusions could be performed 
by any surgeon; however, oxygen introduced by the squeeze pump lead to clotting.  
While various attempts to address this problem existed, a true solution did not present 
itself until 1915.  While it had been known since the 1860s that citrate prevented blood 
clotting, the standard laboratory concentration of 1% proved lethal to recipients.  
Performing a series of simple dose-response experiments, Dr. Richard Lewisohn found 
that a 0.2% concentration was both sufficient to prevent blood clotting, as well as below 
the threshold of citrate toxicity in recipients (Starr 2000).      
 
The new ease of transfusion would allow for some unusual experiments, such as the use 
of cadaver blood in the Soviet Union (Yudin 1937), as well as the discovery and 
identification of plasma.  When blood treated with citrate or any other anticoagulant is 
allowed to sit, it separates into three layers: red cells at the bottom, a thin buffy coat of 
white cells and platelets, and a layer of clear plasma floating at the top.  Plasma was 
found to be useful in treating patients suffering from traumatic shock, such as suffered 
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by individuals exposed to gunfire (Tatum, Elliott et al. 1939).  Lacking fragile red blood 
cells, plasma can be stored for longer periods of time than whole blood making it ideal 
for transatlantic shipping; however, it is nutrient rich and is easily contaminated.  
Seeking a solution to the contamination issue, Dr. Edwin J. Cohn’s laboratory began 
fractionating plasma into its constituent parts.  They characterized the primary protein 
constituents of plasma as fibrinogen, globulins, and albumin.  Albumin was identified as 
a powerful anti-shock agent, which could be shipped in dried form, thereby solving the 
problem of contamination (Cohn, Oncley et al. 1944; Cohn, Strong et al. 1946; Cohn, 
Hughes et al. 1947; Cohn and Wolfson 1948; Cohn 1948). 
 
Like so many other things, the field of hematopoiesis was thrust into modernity through 
tragedy.  After the military deployment of nuclear weapons at the end of the Second 
World War, Japanese began dying of radiation poisoning.  This was unexpected at the 
time, as it was commonly thought that the primary difference between nuclear and 
conventional explosives was the explosive force carried per weight of payload.  By 
observing the symptoms of radiation poisoning, medical scientists hypothesized that 
adult hematopoiesis was a dynamic system supported by primitive cells that could 
differentiate into different kinds of hematopoietic cells, as well as having the ability to 
renew themselves.  The refinement of this hypothesis gave rise to the modern 
understanding of hematopoietic stem (HSC) and progenitor (HPC) cells, as well as the 
hematopoietic hierarchy (Lanza 2004). 
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Identification of the functional HSC 
 
In keeping with its original discovery, an HSC is defined by its ability to completely 
restore the hematopoietic system of a lethally irradiated animal.  In order for this to 
occur, HSCs are required to manifest two distinct capacities: hematopoietic 
multipotency and self-renewal.  Hematopoietic multipotency is the ability of HSCs to 
give rise to all mature blood cell types, while self-renewal is the ability of HSCs to divide 
with at least one daughter cell being an HSC in order to maintain the hematopoietic 
stem cell pool throughout the life of the animal.  Shortly after the HSC was theorized, it 
was demonstrated that bone marrow and spleen cells from healthy animals could 
restore the hematopoietic system in lethally irradiated recipients (Jacobson, Simmons et 
al. 1951; Lorenz, Uphoff et al. 1951), a process which was further refined over the next 
decade.  The spleens of reconstituted mice developed nodules in proportion with the 
quantity of donor bone marrow cells injected (Till and McCulloch, 1961).  Till and 
McCulloch hypothesized that these nodules developed from a single cell: the HSC.   
 
Unfortunately, the initial enthusiasm for colony-forming units-spleen (CFU-S) cells was 
misplaced, and its position in the hematopoietic hierarchy was ultimately clarified.  
Unlike a true HSC, the CFU-S is only able to restore cells of the myeloid lineage and is 
additionally unable to reconstitute a lethally irradiated mouse.  However, treated mice 
do live significantly longer than untreated mice and their hematopoietic system is 
temporarily restored (Till and McCulloch 1964).  This suggested that different grades of 
7 
 
HSCs existed.  At present, HSCs are divided into three classes.  The true, long-term 
repopulating HSC (LTR-HSC) is capable of fully restoring the hematopoietic system of a 
lethally irradiated animal through serial transplantation into secondary, tertiary, and so 
on, recipients (Broxmeyer and Smith 2009).  Intermediate-term repopulating HSCs (ITR-
HSCs) are able to fully restore hematopoiesis in the irradiated animal for up to 32 
weeks, but not through serial transplantation.  Finally, short-term repopulating HSCs 
(STR-HSCs), are capable of fully restoring hematopoiesis in the recipient animal for up to 
16 weeks.  Beneath the STR-HSCs exists progenitor cells which can only restore specific 
hematopoietic populations, amongst them the CFU-S (Broxmeyer and Smith 2009).  As 
ITR- and STR-HSCs exhibit very similar functions, many phenotypic definitions of HSCs do 
not make a distinction between them and simply have LTR- and STR-HSCs with LTR-HSCs 
defined by their ability to repopulate a mouse for over 24 weeks and successfully 
undergo secondary transplantation and STR-HSCs defined in contrast (Broxmeyer and 
Smith 2009).  In a primary transplantation assay, the first three months are thought to 
define the period when STR-HSCs are active and starting with month six defines the 
period when LTR-HSCs are thought to be active, with ITR-HSCs thought to be active 
during the interim period (Chen, Astle et al. 1999; Marshak, Gardner et al. 2001; 
Benveniste, Frelin et al. 2010). 
 
As the CFU-S assay did not describe the HSC, other methods of assessing the quantity 
and behavior of HSCs were necessary.  One early method was limiting dilutions of 
transplanted cells (Jacobson, Simmons et al. 1951; Lorenz, Uphoff et al. 1951).  As HSCs 
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are defined by their ability to rescue a lethally irradiated animal, different treatments 
could be compared by minimum number of cells necessary to rescue a lethally 
irradiated mouse.  This technique is still sometimes employed; however it is ethically 
complicated and fails to account for many of the nuances involved in hematopoietic 
reconstitution.  These issues were addressed by viewing an old technique in a new light.  
Heterologous transplants had been required to demonstrate that cells from the healthy 
donor were indeed responsible for reconstituting the hematopoietic system; however 
this idea was taken to a new level in the 1980s, with the development of the 
competitive repopulation assay using congenic mice (Harrison 1980).  Congenic mice are 
inbred populations of mice that are genetically identical save for one easily recognized 
locus, in hematopoiesis this is normally CD45.  In a competitive repopulation assay, the 
lethally irradiated recipient animal (often a CD45.1 BoyJ mouse, though CD45.1/CD45.2 
C57Bl/6xBoyJ F1 mice are becoming more common) receives a mixture of cells from a 
congenic donor animal (often from CD45.2 C57Bl/6 mice) as well as sufficient 
competitor cells (often from CD45.1 BoyJ mice) to fully restore the hematopoietic 
system in the recipient.  The competitor cells establish a standard whereby the effect of 
different treatments of donor cells can be compared.   
 
Phenotypic identification of the murine HSC 
 
Having developed a sensitive assay for HSC function, defining the phenotype of HSCs 
became a possibility.  This is an area of on-going study, frustrated not by the paucity of 
9 
 
options but by the large number of possibilities and the seemingly arbitrary nature of 
cell surface markers.  The field of phenotypic markers began in the early 1980s when 
mature B cells and their precursors were identified using a single antibody (Coffman and 
Weissman 1981).  Building upon this work, lineage (Lin) markers for a variety of mature 
hematopoietic cells were identified (Muller-Sieburg, Whitlock et al. 1986).  However, 
the absence of lineage markers enriches HSCs but alone is much too heterogeneous a 
population to be of any real scientific use.  The presence of HSCs were further enriched 
in the Lin negative fraction by the expression of stem cell antigen-1 (Sca1) and Thy1.1 
(Spangrude, Heimfeld et al. 1988).  The absence of lineage markers and the presence of 
Sca1 on cells are unambiguous; however, the expression of Thy1.1 was neither positive 
nor negative but “low”, a value difficult to standardize.  This problem was resolved by 
identifying the expression of stem cell factor (SCF) receptor (c-kit) as a replacement for 
the low expression of Thy1.1 (Ogawa, Matsuzaki et al. 1991; Okada, Nakauchi et al. 
1992).  At present, there is broad consensus that Lin-, Sca1+, c-kit+ (LSK) population is 
enriched for HSCs.  This heterogeneous population can be further resolved by the 
presence of cluster domain 34 (CD34), with its absence defining a population further 
enriched for LTR-HSCs and its presence defining a population enriched for STR-HSCs 
(Osawa, Hanada et al. 1996).  As lymphoid populations within the LSK population heavily 
express CD34, HSCs can be further defined by the absence of interleukin-receptor 7 
alpha (IL-7Rα).  This framework has the additional advantage of being able to identify 
several progenitor populations.  CLPs are defined as IL-7Rα+ LSK cells, and the CMP 
population is defined as Lin-, IL-7Rα-, c-kit+, Sca1-.  The CMP population can be further 
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divided into MEPs and GMPs with the use of FcγRIII/II and CD34 with MEPs being 
negative for both and GMPs being positive for both (Katsumoto, Aikawa et al. 2006).  
More stringent phenotypic definitions for each of the three classes of hematopoietic 
cells exist, most especially the LTR-HSCs which are defined by members of the signaling 
lymphocyte activation (SLAM) molecule family (Kiel, Yilmaz et al. 2005; Yilmaz, Kiel et al. 
2006).  SLAM markers CD150, CD48 and CD244 can be used to identify the HSC 
population, described as CD150+, CD48-, and CD244-.  Similar to the LSK-system 
described earlier, SLAM markers can also be used to identify other populations as well: 
MMPs are CD150-, CD48-, CD244+, while lineage-restricted progenitor cells are CD150-, 
CD48+, CD244+ (Van Zant 2006).   
 
Phenotypic identification of the human HSC 
 
As Jacques Monod said, “what is true for E. coli is true for the elephants.” (Friedmann 
2004) and given the conservative nature of evolution it ought to come as no surprise 
that the human HSC essentially behaves in the same manner as murine HSCs.  The 
differences between the two systems lie in the functional assay for HSCs and the 
arbitrary and less definitive set of surface markers which serve to phenotypically define 
HSCs (Weissman and Shizuru 2008). 
 
Phenotypic markers for HSCs are more precisely defined in the murine model.  Analyses 
of human HSCs begin with the CD34+ fraction (Civin, Strauss et al. 1984); though 
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somewhat controversial models do exist where the HSC can be CD34- (Zanjani, Almeida-
Porada et al. 1998).  The primary virtue of the single CD34+ marker is the ease of use in 
clinical settings, where consistent and quick analysis is paramount (Krause, Fackler et al. 
1996).  This population can be further sub-divided by the expression of CD38 
(Terstappen, Huang et al. 1991).  The CD34+ CD38+ population is heavily enriched for 
HPCs while the CD34+ CD38- population is enriched for HSCs.  Though it has not been 
demonstrated to be superior to CD34, some analyses use CD133 instead (Lu, Baudouin 
et al. 2007).  Similar to the murine system, other markers such as CD59, Thy1, c-kit, and 
lineage are available to further resolve these heterogeneous populations.  For example, 
a more stringently but still ill-defined HSC in the human system is CD34+, CD59+, Thy1+, 
CD38lo/-, c-kit-/lo, Lin- (Weissman and Shizuru 2008).  In keeping with the arbitrary and 
unpredictable nature of phenotypic definitions, SLAM markers, which have been so 
effective at defining the murine HSC are insufficient when it comes to the human system 
(Larochelle, Savona et al. 2011).  
 
As no equivalent transplant assay for HSCs is available for humans, a surrogate system 
was developed in immunocompromised mice.  Either non-obese diabetic severe 
combined immunodeficient (NOD/SCID) or NSG (NOD/Shi-scid/IL-2Rαnull) mice are 
sublethally irradiated to create empty hematopoietic niches available for human cells to 
engraft (Lapidot, Pflumio et al. 1992; Ito, Kobayashi et al. 2008).  Similar to competitive 
repopulation in the murine model, the murine cells provide a standard whereby the 
efficacy of different treatments on human cells can be compared. 
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Hematopoietic progenitors 
 
The benefit of hindsight makes it clear that all hematopoietic cells are ultimately derived 
from a single pluripotent HSC.  Initially, hematopoietic populations were examined in 
isolation, first through microscopy (Hajdu 2002) and then through clonogenic colony 
assays (Pluznik and Sachs 1965; Bradley and Metcalf 1966; Pluznik and Sachs 1966).  The 
colony assay in particular was instrumental in clarifying the hematopoietic hierarchy.  
Through careful study it was found that progenitors able to give rise to either 
granulocyte (CFU-G) or monocyte/macrophage (CFU-M) colonies are preceded by 
progenitors that can give rise to both (CFU-GM also known as granulocyte/macrophage 
progenitor, GMP).  Likewise, progenitors able to give rise to proper small erythroid 
colonies (CFU-E) are preceded by those that generate erythroid bursts (BFU-E).  
Megakaryocytes are also generated by their own progenitor cell (CFU-Mk).  Both BFU-E 
and CFU-Mk progenitors are preceded by a megakaryocyte/erythroid progenitor (MEP) 
cell.  Both GMPs and MEPs are preceded by colony forming unit 
granulocyte/erythrocyte/macrophage/megakaryocyte (CFU-GEMM), which is 
synonymous with the common myeloid progenitor cell (CMP).  Similar techniques in the 
lymphoid lineage identified progenitors which specifically gave rise to B and T cells as 
well as a common lymphoid progenitor (CLP).  There exists an even more primitive 
multipotent progenitor (MPP) which is able to give rise to both CMPs and CLPs, which in 
turn is preceded by the HSC itself.  This structure gives rise to the hematopoietic 
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hierarchy, sometimes described as the hematopoietic tree, which is diagrammed in 
Figure 1. 
 
Hematogenesis, hematopoiesis and umbilical cord blood 
 
Adult HSCs reside primarily within the bone marrow, though extramedullary 
hematopoiesis is possible in the spleen and liver.  Intriguingly, hematopoietic 
differentiation is observed in murine embryonic development between E7.0 and E7.5 
whereas condensation of prechodrogenic mesenchymal cells, the first step in bone 
development, does not begin until E8.5 (Tuan 1998).  This means that the eventual site 
of adult hematopoiesis is distinct from the site where HSCs are initially developed.  
Several sites and models of embryonic HSC development have been proposed but all are 
complicated by one of blood’s chief virtues: its dispersed nature.  Unlike solid tissues 
restricted to easily identifiable loci, hematopoietic cells are scattered throughout the 
organism meaning that sites of hematopoietic activity may be distinct from a site of 
hematopoietic development. 
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Figure 1: 
 
  
15 
 
Figure 1:  A schematic representation of the hematopoietic hierarchy. 
 
Hematopoietic development is thought to follow a tightly regulated hierarchy beginning 
with the multipotent hematopoietic stem cell and progressing through a variety of 
progenitor stages before ultimately developing into a mature hematopoietic cell.  While 
recent advances have suggested the hierarchy may not be as rigid as once thought, the 
basic model presented here continues to hold.  Modified from(Weissman and Shizuru 
2008). 
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The first site of hematopoietic activity to be identified was the yolk sac.  In 1907, Wera 
Dantschakoff was the first to note that endothelial cells in chicken embryos appears to 
give rise to hematopoietic cells, findings which were quickly repeated and confirmed in 
a variety of other organisms such as sharks, frogs, turtles, mice, rabbits, pigs, goats, 
sheep, cows, mongooses and humans (Smith and Glomski 1982).  These initial 
discoveries could not be tested until the development of in vitro and in vivo assays 
nearly half a century later.  Initial experiments in birds suggested that transplanted yolk 
sac cells could repopulate the spleen and bone marrow of irradiated avian 
embryos(Moore and Owen 1965; Moore and Owen 1967).  These findings were further 
refined in mice starting in the 1970s.  It was found that the yolk sac contains myeloid 
progenitors from E7.0 to E9.5, after which CFU-S cells are also present (Moore and 
Metcalf 1970; Medvinsky, Samoylina et al. 1993).  True HSCs are not observed in the 
yolk sac until E11.5 (Medvinsky, Rybtsov et al. 2011).  Despite initially promising data on 
the yolk sac, true HSCs appear too late for this to be the site of hematogenesis, forcing 
scientists to look elsewhere. 
 
In 1975 attention turned to a series of experiments performed on birds, where the 
central area (the future body) of a quail blastoderm was grafted to the peripheral area 
of a chick yolk embryo (the future yolk sac).  In contrast to what others (Moore and 
Owen 1965; Moore and Owen 1967) had observed, it was found that hematopoietic 
organs in the chimera where exclusively colonized by cells from the quail (Dieterlen-
Lievre 1975).  These findings were further clarified in the murine model, where it was 
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found that the aorta-gonad-mesonephros (AGM) region of the developing embryo body 
contains HSCs (Godin, Garcia-Porrero et al. 1993).  These HSCs are present at E10.5, a 
full day earlier than in the yolk sac (Gekas, Rhodes et al. 2010).  Studies in several 
species have reaffirmed these studies by demonstrating de novo formation of HSCs 
within the AGM (Gekas, Dieterlen-Lievre et al. 2005; Mikkola, Gekas et al. 2005).  
However, readily transplantable HSCs in the AGM region are only found in low numbers 
and during a short developmental time window suggesting that another site is at least 
partially responsible for HSC development (Kumaravelu, Hook et al. 2002).  Intriguingly, 
blood forming endothelial cells from the yolk sac migrate to the AGM region during 
development, which may help resolve some of the controversy surrounding both the 
yolk sac and AGM region and their role in hematogenesis (Oberlin, Tavian et al. 2002). 
While both the yolk sac and the AGM region contain HSCs and at least the AGM region 
has been shown to be capable of developing HSCs, the inverted hierarchy of early 
hematopoietic development in the embryo has led to the hypothesis that there are two 
waves of hematopoietic development within the embryo (Dzierzak and Speck 2008).  
The first wave, centered on the yolk sac and AGM region, is capable of giving rise to 
macrophages, megakaryocytes and primitive erythrocytes (Chasis 2004; Ou, Chae et al. 
2011).  The second, definitive wave occurs at midgestation and gives rise to the true HSC 
(Dzierzak and Speck 2008).  Having exhausted the yolk sac and the embryo proper, the 
only remaining site for hematogenesis is the placenta.  The placenta is a highly 
vascularized organ, rich in cytokines and growth factors that promote hematopoietic 
colony formation (Burgess, Wilson et al. 1977).  In 2005, HSCs were identified in the 
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placenta at E10.5-E11 (Serikov, Hounshell et al. 2009).  These HSCs undergo a rapid 
expansion starting at E12.5-E13.5 and yielding 15-fold more HSCs than found in the 
AGM region (Serikov, Hounshell et al. 2009), consistent with the two wave hypothesis.  
Furthermore, the placenta is directly upstream of the liver in fetal circulation, which 
suggests that the fetal liver may be primarily colonized by placental HSCs.  Another 
intriguing piece of evidence in favor of placental hematogenesis is the unique properties 
of HSCs derived from umbilical cord blood. 
 
Connecting the placenta to the fetal liver, the umbilical cord was long regarded as 
medical waste.  While HPCs had been identified in umbilical cord blood as early as 1974 
(Knudtzon 1974), the unique properties of umbilical cord blood would not be noticed 
until the late 1980s.  At that time, extensive lab work firmly demonstrated that not only 
are HPCs present in umbilical cord blood, but that umbilical cord blood is heavily 
enriched in HPCs and that these cells can be sent by overnight mail and cryopreserved 
(Broxmeyer, Douglas et al. 1989).  This led directly to the first cord blood transplantation 
by Eliane Gluckman at the Hopital St. Louis in Paris, France.  In October, 1988, HLA-
matched sibling cord blood cells were used to treat a six-year old boy suffering from 
Fanconi anemia (Gluckman, Broxmeyer et al. 1989).  At the time, there were serious 
concerns that cord blood did not contain sufficient HSCs and HPCs to properly engraft in 
a patient and that contamination from maternal cells might enhance graft-versus-host 
disease (Broxmeyer and Smith 2009).  Instead, it became clear that umbilical cord blood 
is a very rich source of clinically relevant HSCs and HPCs and that less, not more, graft-
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versus-host disease is observed.  The first patient to be treated with umbilical cord 
blood is still alive today, 23 years after the procedure and has been cured of the 
hematological manifestations of Fanconi anemia.  In addition to a high concentration of 
HSCs and HPCs and reduced graft-versus-host disease, umbilical cord blood can also be 
easily stored.  The first “proof-of-principle” cord blood bank was established in the 
Broxmeyer laboratory.  Cord blood that has been cryopreserved for as long as 23.5 years 
has been successfully recovered from this bank with high effectiveness as compared to 
fresh cord blood (Broxmeyer 2011).  Since the first umbilical cord blood transplant, 
more than 25,000 human cord blood transplants have been performed treating patients 
with a variety of malignant and non-malignant disorders (Rocha and Broxymeyer 2009).  
The utility of umbilical cord blood is somewhat limited by the low absolute cell number 
as well as a long engraftment time for neutrophils and platelets.  Because the incidence 
and severity of graft-versus-host disease is reduced in umbilical cord blood 
transplantation, there have been attempts to overcome these problems by 
transplanting cord blood from multiple donors.  To date, there has been no rigorous 
proof that two cord bloods are better than one; indeed, in most cases only one of the 
two cord blood collections actually engrafts long-term.  Additionally, multiple cord 
blood transplants have been associated with higher levels of graft-versus-host disease, 
effectively removing one of the advantages this stem cell source presents (Broxmeyer 
2011).  Instead of increasing the number of cells through multiple donors, another 
possibility is to increase the activity of stem cells present in the cord blood.  
Engraftment of HSCs involves at least two separate events: homing of the cells to the 
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bone marrow and then nurturing them for survival, proliferation, self-renewal and 
differentiation within the bone marrow microenvironment (Broxmeyer 2011).  
Increasing the efficacy of stem cell homing could theoretically counteract the small 
donor size.  One promising target to accomplish this feat is stromal cell-derived factor 1 
(SDF1/CXCL12) which binds to CXCR4 present on the HSC.  Not only does SDF1/CXCL12 
act as a chemoattractant, directing the HSC towards the microenvironment, but it also 
enhances the survival of primitive hematopoietic cells (Shaheen and Broxmeyer 2005).  
Through chemical inhibition and knock-out mouse studies, it was found that removing 
CD26/DPPIV activity greatly enhances the effect of both endogenous and exogenous 
SDF1 on HSC homing (Christopherson, Hangoc et al. 2002; Christopherson, Hangoc et al. 
2004).  Despite these problems, the field of umbilical cord blood transplantation has 
already demonstrated great promise for treating disease and holds greater promise still.   
 
The process of hematogenesis remains poorly understood.  The early appearance of 
hematopoietic cells in the yolk sac and AGM region present a case that the initial HSC 
may be developed there.  However, neither site appears to produce enough HSCs to 
fully populate the developing organism.  This has led to a two-wave hypothesis that 
separates the initial primitive hematopoietic development in the yolk sac and AGM 
region from the initiation of lifelong hematopoiesis by HSCs created in the placenta 
(Dzierzak and Speck 2008).  Placental HSCs are both numerous and functionally similar 
to HSCs found in the adult BM.  One difference is that placental HSCs found in the 
umbilical cord appear to be more naïve than adult BM cells, leading to reduced graft-
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versus-host disease in recipients of umbilical cord blood transplants.  Irrespective of the 
site and process of hematogenesis, it is known that afterwards HSCs first migrate to the 
fetal liver and then to the bone marrow where they will remain throughout the life of 
the organism. 
 
The HSC niche 
 
Efforts to better manipulate cells for enhanced engraftment requires an understanding 
of HSC/HPC microenvironmental (niche) within the bone marrow.  While unable to give 
rise to HSCs, there exists within the bone marrow a niche which is able to maintain HSC 
self-renewal.  Perhaps because of its supportive and not developmental role, the precise 
nature of the bone marrow niche was controversial for a very long time.  This 
controversy was no-doubt compounded by the different classes of HSC and the assays 
used to define them.  Early attempts at identifying the niche resulted in two candidate 
cell types at different locations within the bone marrow.  Osteoblasts, located within the 
endosteum of the bone marrow (Lo Celso, Fleming et al. 2009) and endothelial cells 
within sinusoidal blood vessels (Kiel, Yilmaz et al. 2005).  Both cell types are able to 
promote hematopoiesis both in vitro and in vivo, express adhesion molecules consistent 
with their function as the site of the hematopoietic niche and reside in areas of low 
oxygen tension (Taichman and Emerson 1994; Li, Johnson et al. 2004).  While these sites 
do play an important role in hematopoiesis, neither alone was able to satisfactorily 
meet all the criteria of the true hematopoietic niche (Kiel and Morrison 2008).  Recent 
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evidence suggests that the true hematopoietic niche lies in the bone marrow 
endosteum but rather than interacting with an osteoblast, the HSC interacts with 
mesenchymal stem/stromal cells (MSC), beta-adrenergic neurons, macrophages, and 
osteoblasts.  Like the niche candidates, the MSC is able to promote hematopoiesis in 
vivo and in vitro and furthermore it possesses qualities of both osteoblastic and 
endothelial cells, resolving the conflict of which cell type better described the niche.  
Furthermore, the presence of the beta-adrenergic neuron provides a point of contact 
between the neuronal and hematopoietic systems, a relationship which will be 
described in greater detail later (Mendez-Ferrer, Michurina et al. 2010; Chow, Lucas et 
al. 2011).  As the discovery of the MSC-niche is a somewhat recent development, 
information gathered from research pertaining to the older niche-sites will also be 
examined in this thesis. 
 
Relationship between hematopoietic and neuronal systems 
 
There is an increased understanding of hematopoiesis and its regulation by the neuronal 
system, information that may be relevant to enhancing engraftment of HSC/HPCs.  In 
addition to the beta-adrenergic neuron at the hematopoietic niche, the hematopoietic 
and neuronal systems have numerous means of communication with each other.  
Amongst the best studied of these are adrenergic and γ-aminobutyric acid (GABA)ergic 
signaling; however cholinergic and glutamatergic signaling have been investigated.  The 
role of adrenergic signaling in hematopoiesis is fairly straightforward.  Endogenous 
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adrenergic signaling molecules, such as epinephrine, norepinephrine as well as synthetic 
agonists such as methamphetamine stimulate cycling in HS/PCs (Maestroni 1995) and, 
when injected in vivo, stimulate egress from the bone marrow niche (Giudice, Caraglia 
et al. 2010).  While well studied, the role of GABAergic signaling in hematopoiesis 
remains less clear.  Similar to its antagonistic role to adrenergic signaling in the neuronal 
system, exposure to GABA decreases the cycling status of HPCs (Andang, Hjerling-Leffler 
et al. 2008) and the presence of GABA inhibits chemotaxis towards SDF1α (Seidel, 
Niggemann et al. 2007).  However, GABA alone is also a chemattractant for HPCs 
(Zangiacomi, Balon et al. 2009).  Intriguingly, the MSC found at the hematopoietic niche 
have been implicated in GABAergic signaling and can partially compliment the function 
of GABAergic neurons in brain damaged mice (Bae, Han et al. 2007).  The relationship 
between these elements warrants further study.   
 
Cholinergic signaling has also been shown to play an important role in early 
hematopoietic development: exposure of embryonic stem cells to nicotine increases 
differentiation towards the hemagioblast (Serobyan, Jagannathan et al. 2007).  In the 
adult animal, both nicotine and acetylcholine appear to play a proliferative role 
(Gallicchio, Chen et al. 1983; Koval, Zverkova et al. 2008).  Injection of either compound 
in vivo leads to increased leukocyte counts in peripheral blood, bone marrow, and 
spleen.  Furthermore, chronic nicotine exposure results in extramedullary 
hematopoiesis in the spleen (Chang, Forsberg et al. 2010).  In contrast, nicotine 
decreases the production of cytokines within the niche which support HSC proliferation 
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such as IL-3, IL-6, G-CSF, GM-CSF, and IGFBP-3 (Koval, Zverkova et al. 2008).  Nicotine 
exposure also decreases CXCR4 expression on hematopoietic cells, which partially 
explains the decreased engraftment of HSCs in animals exposed to nicotine 
(Khaldoyanidi, Sikora et al. 2001).  Data from knock-out mouse for components of the 
cholinergic system refines these observations.  The absence of β2-containing nicotinic 
receptors favors early myeloid precursor generation whereas absence of α7-containing 
nicotinic receptors favors development of mature myeloid and erythroid cells.  These 
findings mean that under physiological conditions, β2-containing nicotinic receptors 
serve to limit early progenitor generation whereas α7 favors the expansion of immature 
forms. Interestingly, α4β2 nicotinic receptors are inherent to HPCs and more primitive 
cells whereas α7-containing receptors are expressed in both immature and mature 
hematopoietic cells (Koval, Zverkova et al. 2008). 
 
The role of glutamatergic signaling in hematopoiesis is less well understood.  At present, 
α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors do not appear 
to play a role in hematopoiesis based on a search of the NCBI database.  However, there 
are aspects of N-methly-D-aspartic acid (NMDA) receptor function which are related to 
issues of hematopoietic importance.  NMDA receptors have been shown to play a role in 
megakaryocytopoiesis (Genever, Wilkinson et al. 1999; Hitchcock, Skerry et al. 2003) 
thought to be independent of thrombopoietin-mediated effects (Zheng, Yang et al. 
2008).  The NMDA receptor is expressed by osteoclast precursors and activation of the 
receptor is required for osteoclastogenesis (Merle, Itzstein et al. 2003) – a finding which 
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may have implications for the osteoblastic niche.  Furthermore, NMDA receptors are 
particularly susceptible to damage from reactive oxygen species (Bracci, Perrone et al. 
2001), which given the hypoxic nature of the niche may suggest a role for them.  Lastly, 
there is a positive correlation between NMDA receptor-excitation and CXCR4 expression 
(Riviere, Subra et al. 1999).  Much remains to be discovered in this area, and the early 
groundwork justifies further study.  
 
In addition to cross-talk between the hematopoietic and neuronal systems, 
developmental similarities also exist.  Of particular interest are the similarities between 
HSC and neuronal stem cells.  The two stem cell populations have a high degree of 
overlap between both factor and genes involved in their development (Scheffler, Horn 
et al. 1999).  A representative list is provided in Table 1.  Because differences in both 
laboratory techniques available and organ function have led to different emphases in 
research, knowledge gained in one system can be used as a vehicle for discovery in the 
other (Quesenberry, Hulspas et al. 1999; Zhang, Rohlmann et al. 2005).  One such 
discovery is the subependymal zone, the proliferative central core of the central nervous 
system, which was discovered due to its similarity to the bone marrow (Scheffler, Horn 
et al. 1999).  This thesis will employ a similar theoretical approach and examine the role 
of Neurexin I alpha (NRXN1α), a well-studied neuronal protein, in hematopoiesis. 
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The Neurexins 
 
The Neurexins are a conserved family of three proteins, each with two isoforms and 
numerous splice variants for each isoform.  Because of this, they are sometimes 
described as “three genes, 1001 products” (Missler and Sudhof 1998).  Neurexin I alpha 
(NRXN1α), the primary focus of this thesis, was the first member of the family to be 
discovered (Ushkaryov, Rohou et al. 2008) as the receptor for alpha-latrotoxin (LT), the 
component of Latrodectus spp. venom of mammalian relevance and other members 
were identified based on sequence homology (Lise and El-Husseini 2006).  Neurexins are 
single transmembrane proteins with a small internal PDZ domain and a large 
extracellular portion whose structure is determined by the isoform.  The larger alpha-
isoform ranges in size from 160-220kDa and features six Laminin, Neurexin, Sex-
hormone-binding protein domain; also known as a Laminin G domain (LNS) repeats as 
well as an epidermal growth factor (EGF)-like sequence (Lise and El-Husseini 2006).  The 
shorter beta-isoform ranges from 55-95kDa and lacks the EGF-like sequence and 
several, though not all, LNS repeats (Sugita, Saito et al. 2001).  In both isoforms, splice 
variants affect the extracellular domain and tend to alter the LNS domains (Ushkaryov, 
Hata et al. 1994).  The receptor is involved in calcium signaling, synaptogenesis, and  
heterogeneous cell-to-cell adhesion, all mediated by a variety of ligands.  
Neuroligins generally bind the beta-isoform, while DAG1, the Neurexophilins (NXPHs), 
and alpha-latrotoxin each bind the second LNS domain, a unique feature of the alpha-
isoform (Lise and El-Husseini 2006).  After Neuroligin, an intracellular reaction involving 
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Lin2, a ubiquitously expressed scaffolding protein of the MAGUK family, leads to 
opening calcium channels on the cell membrane as well as to additional downstream 
effects mediated by proteins such as Lin7 and Lin10 (Hata, Butz et al. 1996; Craig and 
Kang 2007).  The role of the third family of ligands, the NXPHs, is less well defined; 
however, data suggests that they inhibit Neurexin-mediated signaling within the 
neuronal system (Beglopoulos, Montag-Sallaz et al. 2005; Zhang, Rohlmann et al. 2005)  
 
Data from knock-out animals suggests that Neurexins are able to functionally 
compliment each other (Missler, Zhang et al. 2003), though only NRXN1α appears to be 
expressed in the hematopoietic system (Ivanova, Dimos et al. 2002).  In the neuronal 
system, the primary role of NRXNs appears to be in directing synapse development (Lise 
and El-Husseini 2006).  The beta-NRXNs and Neuroligands play a mutually supportive, 
and necessary, instructive role in generating the synapse.  After beta-NRXN-Neuroligand 
binding, the cell expressing the beta-NRXNs will develop into the pre-synaptic cell 
whereas the cell expressing Neuroligand will develop into the post-synaptic cell.  
Activation of either beta-NRXN or Neuroligand on neuronal cells is sufficient to cause 
them to develop into pre- or post-synaptic cells, respectively and absence of NRXN-
Neuroligand signaling results in aberrant synapse development (Dean, Scholl et al. 
2003).   
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Table 1: 
 
Growth factors, steroids, cytokines, 
and their ligands 
Epidermal growth factor, fibroblast 
growth factors, NGF, brain-derived 
neurotrophic factor, transforming 
growth factors, cilliary neurotrophic 
factor, bone-morphogenetic proteins, 
leukemia inhibitory factor, glial 
growth factor, platelet-derived 
growth factor, tumor necrosis 
factors, insulin-like growth factors, 
interleukins, colony stimulating 
factors, KIT, interferon, retinoic acid, 
T3 
Transcription factors, developmental 
genes, apoptotic and anti-apoptotic 
genes 
bHLH (XATH1), Id2, homeodomain, 
RU49, PBX1, POU, PAX, nuclear-
receptor-type zinc finger, leucine 
zipper, ETS, rel-NFkB, Ikaros, Notch, 
Delta, OCT, neurogenin, neuregulin, 
GLP1, LAG2, Rb, BCL2, BAX, caspases, 
Fas, Fasl, Musashi, Hu 
Extracellular matrix and cell-surface 
proteins 
Tenascin and other glycoprotiens, 
CD34, proteoglycans, adhesion 
molecules, polysialylated neural cell-
adhesion molecule, N-cadherin, 
Dystroglycan, Neurexin I alpha, L1 
and Thy1 
Other Erythropoietin, thrombopoietin, 
silencers (glial-cell missing, neuron-
restrictive silencer factor), cell-cycle-
associated molecules, SHC (SRC-
homology-2-domain-containing 
transforming protein C), 
neuropoietins, Neurexophilin, and 
other cell-signaling molecules 
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Table 1:  Representative elements common to both hematopoietic and neuronal 
development. 
 
A partial list of representative factors and genes common to both the hematopoietic 
and neuronal systems.  Not included are cell cycle-related genes, cyclin-dependent-
kinase inhibitors, and many other elements common to progenitors and stem cells of all 
lineages.  Modified from (Scheffler, Horn et al. 1999). 
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In addition to the importance of NRXN in synapse development, it also appears to play a 
role in what kind of synapse is developed: glutamatergic and GABAergic synapses are 
favored by NRXNs (Craig and Kang 2007).  Specifically, beta-NRXNs induce clustering of 
GABAergic post-synaptic scaffolding proteins Gephyrin and Neuroligand 2, whereas 
Neuroligands 1, 3, and 4 serve as scaffolding proteins for proteins associated with 
glutamatergic synapses (Kang, Zhang et al. 2008).  NRXN1α is also involved in the 
localization of α4β2 nicotinic acetylcholine receptor (nAChR), which modulates the 
efficacy of glutamatergic and GABAergic synapses, to the pre-synaptic cleft (Cheng, 
Amici et al. 2009).  Likewise, alpha-NRXNs are able to directly bind the GABAA receptor, 
increasing the concentration of GABAergic proteins at the post-synaptic cleft (Zhang, 
Atasoy et al. 2010).   
 
In addition to their instructive roles in synapse development, alpha-NRXNs play a critical 
role in modulating the activity of glutamatergic and GABAergic synapses.  The post-
synaptic N-methyl-D-aspartate (NMDA) receptor, which plays an important role in 
glutamatergic signaling, requires alpha-NRXNs to function (Kattenstroth, Tantalaki et al. 
2004).  Similar in function, though opposite in mechanism, alpha-NRXNs are also able to 
bind GABAA receptors and silence them (Zhang, Atasoy et al. 2010).  Intriguingly, this 
means that alpha-NRXN causes synapses to differentiate along an inhibitory line but 
once the synapse is formed alpha-NRXNs serve to support excitatory signaling and 
muffle inhibitory signaling.  Because of this, it is thought that alpha-NRXN serves as a 
mediator between excitatory and inhibitory neuronal signaling (Graf, Zhang et al. 2004).        
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In keeping with its important role in synapse development, NRXN has been associated 
with neurological phenotypes.  Schizophrenia has been associated with disruptions of 
NRXN1 (Kirov, Gumus et al. 2008) as well as Lin2 (Kristiansen, Beneyto et al. 2006), the 
protein directly downstream of NRXN.  NRXN1α also appears to play an important role 
in autism spectrum disorder, as ultra-rare cohorts of particular missense mutations and 
splice variants have been associated with the disorder (Kim, Kishikawa et al. 2008; 
Glessner, Wang et al. 2009); disruption of NRXN1α due to chromosomal breakage has 
also been linked to autism (Kim, Kishikawa et al. 2008).  Interestingly, the chromosomal 
breakage that disrupted NRXN1α appeared to leave NRXN1β unaffected and while some 
correlation between specific missense mutations in NRXN1β and autism have been 
suggested (Feng, Schroer et al. 2006; Kim, Kishikawa et al. 2008); family data suggests 
that incomplete penetrance occurs (Yan, Noltner et al. 2008).  These associations may 
prove of interest to the investigation of the hematopoietic role of this signaling axis.  
While the neuronal aspects of these diseases are well documented and involved in 
diagnosis (Broyd, Demanuele et al. 2009), both diseases also manifest a distinct 
hematopoietic phenotype.  Schizophrenics and autistics posse a pro-inflammatory 
phenotype coupled with an increase in the absolute number and cycling status of many 
hematopoietic populations including HPCs (Malacarne and Dallapiccola 1969; Wilke, 
Arolt et al. 1996; Muller, Riedel et al. 2000; Cohly and Panja 2005).   
 
Because of its many binding partners, a diagram of NRXN1α and its binding partners is 
provided in Figure 2. 
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Figure 2: 
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Figure 2:  A schematic representation of the relationship between NRXN1α and its 
binding partners. 
 
NRXN1α sits at the center of a complex and tightly regulated system.  Though it 
possesses six LNS domains, most ligands bind either the second or the sixth.  The sixth 
LNS domain is primarily involved in GABAergic signaling and binds Gephyrin, 
Neuroligand 2, and GABAA receptor.  When NRXN1α is bound to GABAA receptor it is 
unable to respond to GABA.  In addition to binding NRXN1α, Gephyrin and Neuroligand 
2 also bind GABAA receptor and help recruit it to the synapse.  The endogenous activity 
of the second LNS domain is less well understood but it is the principle binding site for 
LT.  In addition to LT, there are two endogenous ligands for the second LNS domain: 
NXPH and DAG1.  NXPH also binds to LT.  Lastly, NRXN1α is required for NMDA function 
though the binding site has not been defined.  Drawing not to scale, NRXN1α has been 
presented as a branching protein for ease of viewing and does not reflect the actual 
structure. 
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Dystroglycan 
 
Dystroglycan (DAG1) is a ubiquitously expressed transmembrane glycoprotein encoded 
by a single gene, dag1, whose product is cleaved into a larger 120-190kDa alpha-subunit 
non-covalently bound to a smaller 43kDa transmembrane beta-subunit.  DAG1 is the 
central component of the dystrophin-associated glycoprotein complex and serves as an 
interface between the cytoskeleton and extracellular matrix.  As such, DAG1 is a 
receptor for multiple extracellular matrix proteins such as Agrin, Laminin, Perlecan, etc 
(Williamson, Henry et al. 1997).  DAG1 can also bind NRXN1α, which is most commonly 
observed in the brain where normal components of the extracellular matrix are absent 
(Sugita, Saito et al. 2001).  Within the cell, beta-Dystroglycan function is normally 
associated with dystrophins and syntrophins (Drysdale and Crosby 2005), though it has 
also been associated with FYN, C-src tyrosine kinase, Src, NCK1, SHC1, Caveolin-3 
(Sotgia, Lee et al. 2000), and Grb2 (Yang, Jung et al. 1995).  
 
In addition to its role in muscle and brain tissue, DAG1 also plays a role in the 
hematopoietic system.  Blocking DAG1 in the thymus prevents T-cells from undergoing 
positive selection (Zhang, Wang et al. 2006).  DAG1 is also the second most highly 
expressed protein on the surface of cells thought to form the osteoblastic niche for 
hematopoietic stem cells (Hines, Nielsen et al. 2008).  Additionally, DAG1 knock-out 
mice fail to develop a mesoderm, the embryonic tissue from which hematopoietic cells 
arise (Williamson, Henry et al. 1997).  Lastly, beta-Dystroglycan is a target for cleavage 
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by MMP-9 (Michaluk, Kolodziej et al. 2007) a protease involved in HSC homing during 
transplant (Lapidot, Dar et al. 2005). 
 
The Neurexophilins 
 
Neurexophilins were first discovered in the hunt for the receptor for LT (Davletov, 
Krasnoperov et al. 1995; Geppert, Khvotchev et al. 1998): in addition to NRXN1α, a small 
29kDa protein bound LT on the column.  Further study revealed that this protein, 
NXPH1, also binds NRXN1α (Missler, Hammer et al. 1998).  Through comparison of 
genomic DNA sequences, four homologous proteins were found within mammals, 
though members of the family exist throughout the animal kingdom.  Of these, NXPH1, 
2, and 3 were found to found to bind NRXN1α and can compliment each other in knock-
out animals (Missler and Sudhof 1998).  NXPH4, on the other hand, is not normally 
included within the family as it has different binding partners and function: the name 
remains as a historical artifact (Beglopoulos, Montag-Sallaz et al. 2005; Lise and El-
Husseini 2006).   
 
Aside from binding NRXN1α, the function of NXPH family members remains unclear.  
Double knock-out mice are viable and do not appear to have any clear abnormalities 
aside from an increased startle response (Beglopoulos, Montag-Sallaz et al. 2005).  In 
mice, NXPH1 is located primarily in the spleen, NXPH2 is found in the kidney and NXPH2 
and NXPH3 are secreted by a small subset of inhibitory neurons in the brain (Petrenko, 
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Ullrich et al. 1996; Clarris, McKeown et al. 2002; Craig and Kang 2007).  Furthermore, 
microarray data has implicated high NXPH expression in macrophages during immune 
system exhaustion (Rodriguez, Chang et al. 2004) and NXPH expression in many cancers 
correlates with a negative prognosis (Warnat, Oberthuer et al. 2007; Faria, Miguens et 
al. 2008; Knight, Skol et al. 2009; Song, Ramus et al. 2009).  Both NXPH and DAG1 bind 
to the second LNS domain on the alpha-NRXNs, suggesting a possible antagonism 
between the two ligands (Beglopoulos, Montag-Sallaz et al. 2005).   
 
Hypothesis 
 
Given its inhibitory role in a neuronal context as well as its presence in 
immunosuppressive conditions, we hypothesized that NXPH plays an inhibitory role in 
hematopoiesis.  This inhibition could be either a direct function of NXPH-NRXN1α 
binding, or by indirectly antagonizing DAG1-NRXN1α interaction.  Using recombinant rat 
NXPH1 and a well-established DAG1 blocking antibody, we investigated a role for the 
DAG1-NRXN1α axis in human and murine hematopoiesis.  In mice in vivo, our results 
suggest that NXPH1 plays a myelo- and lymphosuppressive role.  In vitro, NXPH1-
mediated inhibition of HPC proliferation is antagonized by endogenous DAG1.  
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Materials and methods 
 
Antibodies and reagents 
 
For ﬂow cytometry, anti-mouse (mu) antibodies against c-Kit, Sca-1, FcγR III/II, IL-7Rα, 
lineage cocktail (CD3, CD14, CD16, CD19, CD20, and CD56), and isotype control 
antibodies were from BD Biosciences (San Diego, CA).  Anti-mu CD34 antibody was from 
eBioscience (San Diego, CA) and anti-mu sca-1 and lineage cocktail were purchased from 
BioLegend (San Diego, CA).  Anti-human (hu) CD34, and CD38 were from Biolegend and 
Miltenyi Biotec (Auburn, CA) and an anti-hu lineage cocktail was from BD Biosciences.  In 
human tissues, DAG1 was analyzed using IIH6 antibody (Santa Cruz; Santa Cruz, CA) and 
a PE-conjugated anti-mouse IgM (Santa Cruz); NRXN1α was analyzed using N-16 
antibody (Santa Cruz) and APC-conjugated anti-goat IgG antibodies (R&D Biosciences; 
Minneapolis, MN).  In murine tissue, DAG1 was analyzed using abcam ab43120 (San 
Francisco, CA) and an APC-conjugated anti-rabbit IgG (Thermo Scientific, Barrington, IL) 
for flow cytometry and an HRP-conjugated anti-rabbit IgG antibody (Thermo scientific) 
for immunohistochemistry; NRXN1α was analyzed using N-16 antibody (Santa Cruz) and 
APC-conjugatred anti-goat IgG antibodies (R&D Biosciences) for flow cytometry and 
Synaptic Systems (Goettingen) antibody 175 002 and Thermo Scientific HRP-conjugated 
anti-rabbit antibody for immunohistochemistry.  Prior to sorting, the CD34+ population 
of huCB and the lineage negative population of mu bone marrow (BM) were enriched 
via MACS (Miltenyi Biotec, Auburn, CA).  Antibodies for Western blots were: anti-
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NRXN1α mouse monoclonal antibody (BD Pharmigen; San Diego, CA), anti-NRXN1α goat 
polyclonal antibody, anti-NXPH1 goat polyclonal antibody (Santa Cruz Biosystems, Santa 
Cruz, CA), and anti-beta-actin mu monoclonal antibody (Sigma, St. Louis, MO).  
Recombinant rat NXPH1 and NRXNα were from R&D Systems (Minneapolis, MN).  All 
murine recombinant cytokines including stem cell factor (SCF), granulocyte 
macrophage-colony stimulating factor (GM-CSF), and interleukin-3 (IL-3), as well as 
human recombinant interleukin-8 (IL-8) were from R&D systems.  Human recombinant 
cytokines including SCF, GM-CSF, IL-3, thrombopoietin (TPO), and fms-like tyrosine 
kinase receptor-3 ligand (Flt3L) were from either BioVision (Mountain View, CA) or R&D 
Systems.  Recombinant human erythropoietin (EPO) was from Amgen (Thousand Oaks, 
CA).  Fetal Bovine Serum (FBS) was from Hyclone (Waltham, MA).  Growth media 
including IMDM and RPMI-1640 were from Gibco (Invitrogen, Carlsbad, CA) and 
McCoy’s 5A was from Sigma.  Dulbecco’s Phosphate Buffered Saline (DPBS) was from 
Gibco, and only used during in vivo injections; otherwise Phosphate Buffered Saline 
(PBS) from Lonza (Walkersville, MD) was used.  Pokeweed mitogen mouse spleen cell 
conditioned medium (PWMSCM) was produced (Cooper and Broxmeyer 1991).  
Propidium iodide and bromo-deoxyuridine (BrdU) were purchased from Sigma. 
 
Mice 
 
C57Bl/6 mice were purchased from Jackson laboratories (Bar Harbor, ME), and housed 
in a conventional animal facility.  BoyJ mice and C57/BoyJ F1 mice were bred at Indiana 
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University Laboratory Animal Resource Center.  Studies were approved by the Indiana 
University Animal Care and Use Committee.  In some cases, mice were intravenously 
injected with either sterile pyrogen-free DPBS or NXPH1, in the presence or absence of 
BrdU.  Some mice were intraperitonously injected with rapamycin (Sigma) in addition to 
the other compounds listed here.  All materials were purchased certified endotoxin free.  
 
Human CB and peripheral blood (PB) 
 
Cord blood and PB were obtained with institutional review board approval.  Low-density 
(LD) mononuclear CB cells and plasma were isolated by density gradient centrifugation 
over Ficoll-Plaque Plus (Amersham Pharmacia Biotech).  CD34+ cells were enriched via 
MACs.  After enrichment, cells were sorted by FACS to a final purity of >98% CD34+.  Red 
Blood Cell (RBC) lysis buffer was used in all cases to remove erythroid cells. 
 
Expansion of CD34+ cord blood cells 
 
Enriched CD34+ cells were expanded as previously described (Broxmeyer, Hangoc et al. 
1992) with some minor modifications.  Cells were cultured in RPMI-1640 in 1% FBS in 
the presence of 50ng/ml rhu SCF, 100ng/ml rhu TPO, and 100ng/ml rhu Flt3L.  Cells 
were then washed and used directly in colony assays or labeled with anti-human 
antibodies and examined via FACS. 
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Flow cytometry analysis of surface markers, sorting, and plating 
 
Freshly harvested murine bone marrow cells were washed and resuspended in PBS + 
2mM EDTA (ethylenediaminetetraacetic acid) + 0.5% bovine serum albumin (BSA), 
incubated for 10 minutes at room temperature with Fc-block (Miltenyi Biotech) and 
then incubated for one hour at 4oC with the recommended volume of anti-murine 
antibodies: lineage cocktail conjugated to APC, c-kit conjugated to PE/Cy5, sca1 
conjugated to PE, and CD34 conjugated to FITC.  After incubation, cells were washed 
and resuspended in PBS and kept at 4oC until sorting by FACSAria (BD Biosciences 
Immunocytometry Systems, San Jose, CA).  Both freshly harvested and cytokine 
expanded human CD34+ cells were stained with anti-human antibodies: CD34 
conjugated to either FITC or PE.  Sorted cells were normally collected into a solution of 
PBS + 2mM EDTA + 0.5% BSA, washed, and then resuspended at an appropriate working 
concentration in IMDM.  In the case of single cell plating, single CD34+ cells were directly 
sorted into one well of a 96-well microtiter plate containing 100µl methylcellulose 
culture medium.  Cultures contained IMDM, 1% methylcellulose, 30% FBS, as well as 
several different cytokines, each alone or in combination.  At least 216 wells were used 
per experimental point per experiment. 
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Phenotypic Analysis 
 
The following stem and progenitor populations were assessed: long-term repopulating 
HSCs (LTR-HSC; lineage-,sca-1+,c-kit+, IL-7Rα-, CD34-), short-term repopulating HSCs (STR-
HSC; lineage-, sca-1+, c-kit+, IL-7Rα-, CD34+) common lymphoid progenitor (CLP; lineage-
, sca1+, c-kit+, IL-7Rα+), megakaryocyte/erythroid progenitor (MEP; lineage-, sca1-, c-kit+, 
CD34-, FcγR-/lo), common myeloid progenitor (CMP; lineage-, sca1-, c-kit+, CD34+, FcγR-/lo), 
and granulocyte/macrophage progenitor (GMP; lineage-, sca1-, c-kit+, CD34+, FcγR+/hi).  
Bone marrow from mice was collected and stained with antibodies to surface markers 
as previously described (Katsumoto, Aikawa et al. 2006).  Data was collected from the 
samples using a LSR II (BD) instrument and BD FACSDiva software (BD,San Diego, CA).  
Data was analyzed using WinList software (Verity Software House, Topsham, ME). 
 
HPC colony assay 
 
Methylcellulose and agar HPC assays were performed as described previously 
(Broxmeyer, Orschell et al. 2005).  Mouse BM cells were plated at 5x104 cells/ml, while 
murine spleen cells were plated at 5x105 cells/ml.  Cultured in triplicate, the murine cells 
were incubated in a humidified atmosphere, 5% CO2 and lowered (5%) O2 at 37oC for 7 
days.  Low-density huCB cells were plated between 1-5x104 cells/ml while CD34+ 
enriched cells were plated between 1-5x102 cells/ml.  Human cells were cultured under 
the same conditions as the murine cells, but with human cytokines, and colonies 
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counted after 14 days incubation.  After specified time in culture, cells were scored for 
colonies formed from colony forming unit-granulocyte-macrophage (CFU-GM).  In the 
presence of Epo, burst forming unit-erythroid (BFU-E), colony forming unit-granulocyte, 
erythroid, macrophage, megakaryocte (CFU-GEMM), and total colony forming units 
(CFU-Total) were counted in addition to CFU-GM.  Absolute numbers of murine HPCs 
per femur were calculated based on the total nucleated cellularity per femur and the 
number of HPC colonies in that number of nucleated cells.  High specific activity tritiated 
thymidine kill assay was used to estimate the cycling status of HPC (= percent of HPC in 
S-phase) (Broxmeyer, Orschell et al. 2005).  To address the issue of DAG1 presence on 
hu and mu hematopoietic cells, cells were treated for one hour using the well described 
(Zhang, Wang et al. 2006) IIH6 blocking antibody and then plated.  Survival during 
delayed growth factor addition was assayed by plating hu and mu cells as normal in 
IMDM, methylcellulose, glutamine, and FBS absent any growth factors.  After 0 
(control), 24, or 48 hours a standard concentration of growth factors and growth factor 
combinations was added.  Colonies were scored as normal. 
 
Migration assay 
 
Chemotaxis assays were performed as previously described (Basu, Ray et al. 2007) with 
both mu total BM (final concentration: 5x104 cells/ml) and hu CD34+ cells (final 
concentration: 5x104).  Mu total BM cells were plated in semisolid culture, whereas 
human CD34+ cells were first counted via flow cytometry.   
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Western blotting and ELISA 
 
For protein expression, both LD muBM and huCB cells were cultured in RPMI + 10% FBS 
and incubated overnight in a humidified atmosphere, 5% CO2 and 5% O2 at 37oC with 
growth factors shown.  Cells were washed with ice-cold PBS and lysed.  After lysis, the 
solution was exposed to centrifugation at 14000g for 30 minutes at 4oC.  Protein content 
of lysates was quantified using bicinchonic acid protein assay reagent (Pierce, Rockford, 
IL) and samples were adjusted to equal protein concentration.  Total cell lysates were 
resolved in 4-20% gradient sodium dodecyl sulfate (SDS)-polyacrylamide gels 
(Invitrogen) and transferred to Hybond membrane (Millipore, Bedford, MA).  Filters 
were blocked using 5% BSA in Tris (tris(hydroxymethyl)aminomethane)-buffered 
saline/Tween-20 (TBST) for 1 hour and incubated overnight with antibodies.  
Membranes were washed with TBST and incubated with secondary antibodies 
conjugated to horseradish peroxidase, and antibody binding was detected by enhanced 
chemiluminescence (ECL) reaction (GE).  Enzyme-linked immunosorbent assay (ELISA; 
reagents from BD Pharmingen or R&D Systems) was performed as previously described 
(Mathur, Chang et al. 2006) to measure concentrations of NXPH in muBM, both hu and 
mu PB plasma, as well as huCB plasma.  Polyclonal antibody raised against full-length 
recombinant rat NXPH1 (R&D Systems) was used to ensure a high degree of cross-
species reactivity, likely with little resolution between NXPH1 and other NXPH-family 
members.   
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Cell cycle analysis 
 
In addition to the high specific activity tritiated thymidine kill assay, cycling status of 
phenotyped HSCs and HPCs was assayed via PI and BrdU uptake (Gratzner, Leif et al. 
1975).  C57Bl/6 mice were injected i.v. with either carrier (DPBS) plus 1mg BrdU or 5µg 
NXPH1 plus 1mg BrdU.  BrdU (0.8mg/ml) was also added to the drinking water at the 
time of injection.  Twenty-four hours post-injection, BM cells were harvested, washed, 
and stained for sorting via FACS.  After sorting, cells were washed and resuspended in a 
small volume of ice-cold FBS.  Cells were then gently vortexed while ice-cold fixative 
(95% EtOH and 5% acetic acid) was added to the solution.  Cells were allowed to fix for 
two hours at 4oC under fluorescent lights.  Fixed cells were washed and resuspended in 
PBS and RNase.  After RNase digest, DNA was denatured by resuspension in 2N HCL plus 
Triton X-100.  After 30 minutes, cells were pelleted and washed with 0.1M Na2B4O7 to 
neutralize any remaining acid.  Fixed cells were washed three times and resuspended in 
PBS + 1% tween + 2% BSA and probed with FITC conjugated anti-BrdU antibodies and 
stained with PI.  Cells were then analyzed via flow cytometry. 
 
PB analysis 
 
At either twenty-four or forty-eight hours after i.v. injection of NXPH1, PB was collected 
by cardiac puncture.  Blood was analyzed using a Hemavet (Drew Scientific Inc, Oxford, 
CT). 
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Competitive repopulation assay 
 
This was performed as described (Campbell, Basu et al. 2009).  Briefly, 5x105 unsorted 
BM cells from C57/Bl6 mice (CD45.2) treated twenty-four hours earlier with either 5µg 
NXPH1 or carrier (DPBS) were mixed with 5x105 BoyJ (CD45.1) BM cells and injected by 
tail vein into C56/Bl6:BoyJ F1 double-positive recipients (CD45.1:CD45.2) which had 
been total body irradiated with 9.5 Gy.  After seven months, BM was analyzed by flow 
cytometry using fluorescent conjugated anti-CD45.1 and CD45.2 antibodies and lineage 
specific markers (BD Biosciences).  After seven months, 5 secondary recipients per 
treatment group were transfused with pooled BM from at least 4 members of the 
corresponding primary transplant group.  Four months after the secondary transplant, 
BM was harvested and analyzed for percent chimerism was analyzed 
 
Immunohistochemistry 
 
Mouse femurs were dissected and demineralized in a solution of 10% EDTA and 4% 
phosphate-buffered formalin and then infiltrated with paraffin and sectioned.  
Detection of DAG1 and NRXN1α expression on paraffin-embedded tibiae from 8-16-
week-old mice was performed as previously described (Rhee, Allen et al. 2011).  Briefly, 
sections were deparaffinized, treated with 3% H2O2 to inhibit endogenous peroxidase 
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activity, blocked with goat serum, and then incubated with either a 1:500 dilution of 
rabbit polyclonal anti-mouse α-DAG1 antibody or rabbit polyclonal anti-mouse NRXN1α 
antibody.  Sections were then incubated with goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody.  Color was developed with a diaminobenzidine 
substrate chromogen system and counterstained with methyl green dye.  Non-immune 
IgGs were used as negative controls. 
 
Statistical analysis 
 
Student unpaired 2-tailed t test was used for statistical analysis, except for the HPC 
colony assay where single CD34+ cells were plated per well, in which case Fischer’s exact 
test was employed.  In experiments involving multiple variables, analysis of variance 
(ANOVA) was employed between the groups to control for false positives.  The level of 
significance is indicated by P value.  Non-linear regression analysis was used to generate 
trend lines.  The goodness of fit is indicated by R2 value. 
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Results 
 
Expression of DAG1, NRXN1α and NXPH in huCB 
 
Previous studies in both the human (hu) and murine (mu) systems suggest that DAG1 
(Williamson, Henry et al. 1997; Hines, Nielsen et al. 2008) and NRXN1α (Ivanova, Dimos 
et al. 2002) may play a role in hematopoietic development.  Furthermore, DAG1 has 
already been shown to be present on a high percentage of CD34+ cells (Steidl, Bork et al. 
2004).  We found DAG1 and NRXN1α present on nearly all CD34+ cells.  Intriguingly, the 
more primitive CD34+ CD38- population can be further subdivided into two distinct 
populations based on DAG1 and NRXN1α expression (Figure 3); however these 
populations do not appear to differ in their proliferation in vitro, nor in their expression 
of molecules thought to be important to stem cell function such as c-kit, Thy1, CD150, 
CXCL12 and E-cadherin (used as a control).  Percentage of cells expressing DAG1 and 
NRXN1α decreased as cells differentiated: only a third of lineage positive cells expressed 
either protein.  We could not identify a significant population expressing NXPH via 
extracellular flow cytometry; however ELISA reveals a high concentration 
(461.7±59.7ng/ml) of NXPH in huCB plasma as compared to FBS (8.1±2.1ng/ml) and 
adult huPB plasma (5.8±0.8ng/ml). 
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Recombinant NXPH1 inhibits colony formation in vitro and is antagonized by 
endogenous DAG1. 
 
Having established the presence of NRXN1α in huCB HPCs, recombinant NXPH1 was 
used to assay its function.  When low-density huCB cells are plated at a concentration of 
1x104cells/ml, NXPH1 (200ng/ml) selectively inhibits proliferation stimulated by GM-
CSF+SCF (Figure 4) but not SCF, GM-CSF, IL-3, IL-3+SCF and GM-SCF+IL-3+SCF+Epo.  
Since DAG1 and NRXN1α are involved in calcium signaling, and calcium ionophores are 
known survival agents, we hypothesized that DAG1-NRXN1α interaction elicited a pro-
survival effect from HPCs, an interaction which was antagonized by recombinant NXPH1.  
To test for this, huCB cells were pre-incubated with a DAG1 blocking antibody.  
Consistent with this hypothesis, cells stimulated with GM-CSF+SCF proliferated less 
when pre-incubated with the DAG1 blocking antibody than with the isotype control 
(Figure 5A).  Unexpectedly, when the blocked cells were exposed to recombinant 
NXPH1, they were inhibited under all growth conditions save SCF alone (Figures 5A and 
5B). 
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Figure 3: 
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Figure 3:  NRXN1α and DAG1 are expressed on primitive and more differentiated 
hematopoietic cells in huCB.   
 
Top:  Representative FACS plot of the expression of NRXN1α and DAG1 in huCB Lin+, 
CD34+, CD34+ CD38+, and CD34+ CD38- populations. 
 
Bottom:  Chart displaying percentages of huCB populations expressing NRXN1α and 
DAG1 (combined data from at least three independent experiments; mean±SD).  
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Figure 4: 
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Figure 4:  Recombinant NXPH1 selectively inhibits proliferation stimulated by GM-
CSF+SCF in huCB cells in vitro.   
Percent recombinant NXPH1-mediated inhibition of CFU-GM colony formation in 
primary huCB cells plated as a population under a variety of factor-stimulated growth 
conditions (3 combined independent experiments, each done in triplicate; percent 
inhibition is calculated from the control defined as zero percent inhibition; mean±SD).   
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Figure 5: 
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Figure 5:  DAG1 antagonizes NXPH1-mediated inhibition in vitro. 
 
A:  Percent recombinant NXPH1-mediated inhibition of CFU-GM, BFU-E, and CFU-GEMM 
colonies produced by huCB-derived HPCs stimulated by GM-CSF, IL-3, SCF, and Epo, in 
the presence and absence of anti-DAG1 blocking antibody when plated in population 
(combined data from three independent experiments performed in triplicate; percent 
inhibition is calculated from the control defined as zero percent inhibition; mean±SD). 
 
B:  Percent recombinant NXPH1-mediated inhibition of CFU-GM colonies produced by 
huCB-derived HPCs stimulated by specific growth factors, alone or in combination, in the 
presence and absence of anti-DAG1 blocking antibody when plated in population 
(combined data from three independent experiments performed in triplicate; percent 
inhibition is calculated from the control defined as zero percent inhibition; mean±SD).   
 
*p<0.05, **p<0.005, ***p<0.0005. 
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As endogenous DAG1 appear to be a complicating factor, we sorted individual huCB 
CD34+ cells to single wells to determine if the suppressive effect was at level of 
progenitor cells.  Recombinant NXPH1 inhibited proliferation of CFU-GM, BFU-E and 
CFU-GEMM progenitors stimulated by GM-SCF+IL-3+SCF+Epo (Figure 6A).  Because 
recombinant NXPH1 may have been interacting with a previously unrecognized partner, 
cells were also cultured in the presence of recombinant NRXN1α.  Recombinant 
NRXN1α did not appear to affect proliferation; however it did decrease the inhibitory 
effect of recombinant NXPH1 suggesting that recombinant NXPH1 does signal through 
NRXN1α and exogenous NRXN1α competes with endogenous NRXN1α for binding.  It 
remains unknown whether NRXN1α is internalized under these conditions; however, we 
feel it is unlikely.  If recombinant NRXN1α were being internalized, we would expect to 
see an increase in the inhibitory effect of recombinant NXPH1 in the samples where 
both recombinant NRXN1α and NXPH1 are present and this is not observed.  
Furthermore, NRXN1α is a very large protein (165-175kDa), making internalization 
difficult for the cell.  To ensure DAG1 had no effect on individual CD34+ cells, CD34+ cells 
were treated with DAG1 blocking antibody (Figure 6B).  Consistent with our 
hypothesized role for DAG1, no difference was observed was observed between the 
treated and untreated cells at a single cell level.  The effect of recombinant NXPH1 on 
individually plated CD34+ cells cultured in the presence of SCF, GM-CSF, IL-3, GM-
CSF+SCF and IL-3+SCF was also assessed.  At a single cell level, recombinant NXPH1 
suppresses colony forming ability under all conditions save SCF alone (Figure 7), which is 
consistent with the huCB cells plated in a population after treatment with anti-DAG1 
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Figure 6: 
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Figure 6:  Recombinant NXPH1 directly inhibits colony forming ability of primary huCB 
HPCs.   
 
A:  Percent of wells containing individually plated huCB CD34+ cells producing CFU-GM, 
BFU-E, and CFU-GEMM colonies in the presence of recombinant NXPH1, and/or NRXN1α 
(252 wells were evaluated for each point; mean±SD).  
 
B:  Percent of wells containing individually plated huCB CD34+ cells producing CFU-GM, 
BFU-E and CFU-GEMM colonies in the presence of recombinant NXPH1 and/or anti-
DAG1 blocking antibody (252 wells were evaluated for each point; mean±SD). 
 
*p<0.05  
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Figure 7: 
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Figure 7:  Inhibition of huCB HPC colony formation by recombinant NXPH1 is not growth 
factor dependent. 
 
Percent of wells containing individually plated huCB CD34+ cells grown under a variety of 
conditions in the presence and absence of recombinant NXPH1 producing CFU-GM 
colonies (over 500 wells were evaluated for each point; mean±SD).   
 
**p<0.005, ***p<0.0005. 
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blocking antibody (Figure 5).  Furthermore, colonies that developed in the presence of 
recombinant NXPH1 were smaller than those in the controls (Figure 8).   
 
Though single cell assays suggested that the effect of NXPH1 on HPCs was a direct one, 
the difference between single cell and population culture warranted further 
investigation.  If the inhibitory effect of NXPH1 on HPCs stimulated by GM-CSF+SCF in a 
population of cells is fundamentally different from other growth factor and growth 
factor combinations, pre-treatment might provide some insight on this matter.  
However, pulse pre-treatment of huCB cells with NXPH1 did not affect HPC proliferation 
(Figure 9A).  We also considered the possibility of an indirect effect.  To account for 
possible secondary effects, conditioned medium from LDCB cells exposed overnight to 
NXPH1 was generated.  Low-density huCB cells were cultured in 20% conditioned 
medium alone, with SCF, GM-CSF, or GM-CSF+SCF.  Conditioned medium from cells 
cultured in the presence of recombinant NXPH1 was not inhibitory to growth stimulated 
by conditioned medium alone, SCF, GM-CSF, or GM-CSF+SCF (Figure 9B).   
 
Consistent with our previous results, recombinant NXPH1 directly inhibits HPC 
proliferation and endogenous DAG1 is the agent that blocks its effects in vitro.  
Together, these results suggest that recombinant NXPH1 binds NRXN1α and directly 
inhibits huCB HPC proliferation.  This inhibitory effect is blocked by the presence of  
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Figure 8: 
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Figure 8:  Recombinant NXPH1 decreases CFU-GM colony size. 
 
Size of CFU-GM colonies produced by individually plated huCB CD34+ cells grown under 
a variety of conditions in the presence and absence of recombinant NXPH1 
(representative colonies were randomly selected for display). 
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Figure 9: 
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Figure 9:  Recombinant NXPH1 directly inhibits proliferation of HPCs stimulated by GM-
CSF+SCF. 
 
A:  The effect of recombinant NXPH1 pulse pre-treatment on huCB proliferation 
expressed as percent control (GM-CSF).  Control cells were plated with either DPBS 
carrier or 500ng/ml NXPH1.  Experimental cells were pre-treated with either DPBS 
carrier or 500ng/ml NXPH1, washed and then plated.  (At least three independent 
experiments performed in triplicate were used for calculating data points; mean±SD).   
 
B:  The effect of conditioned medium from NXPH1 treated cells expressed as CFU-GM 
colony forming ability.  1x106 LDCB cells/ml were cultured in RPMI-1640 + 10% FBS 
medium in the presence or absence of 500ng/ml NXPH1.  Conditioned medium was 
collected after 24 hours and sterile filtered.  20% conditioned medium was used in 
conjunction with nothing (-), SCF, GM-CSF, or GM-SCF+SCF.   
 
*p<0.05 
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DAG1 under all conditions save GM-CSF+SCF, (events evaluated later in the murine 
system). 
 
Because NXPH is present in huCB plasma, we hypothesized that it might have an effect 
on ex vivo culture of HPCs.  To test this, huCB CD34+ were isolated via MACS and 
cultured as a population of 1x104cells/ml for three days in the presence of SCF 
(50ng/ml), TPO (100ng/ml), and Flt3L (100ng/ml) plus or minus NXPH1 (200ng/ml).  
After the initial culture, single CD34+ cells from the two conditions were sorted via FACS 
and, as per above, plated as a single cell per well in the presence or absence of 
200ng/ml NXPH1 under maximally stimulatory conditions (Epo, SCF, IL-3, and GM-CSF).  
The presence of NXPH1 did not have an effect on the expansion of HPCs in terms of fold 
expansion and colony forming ability and the cells produced were responsive to 
inhibition by recombinant NXPH1 (Figure 10).  This argues against the involvement of 
NXPH in the self-renewal of HSCs derived from huCB. 
 
Alpha-latrotoxin has a pro-survival effect on HPCs which is blocked by NXPH1 
 
In addition to NXPH and DAG1, the second LNS domain of NRXN1α also binds LT.  In the 
neuronal system, LT binds NRXN1α and inserts itself into the cellular membrane forming 
a calcium ionophore, which is responsible for the effects of latrodectus spp. venom on 
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mammals.  Because calcium ionophores have been previously shown to have a pro-
survival effect on HPCs, we tested the effect of LT on HPC survival under delayed growth 
factor addition.  Similar to other calcium ionophores, LT did not affect HPC proliferation 
under normal conditions but did act as a pro-survival factor in the context of delayed 
growth factor addition in vitro (Figure 11A).  In addition to binding the same LNS domain 
as NXPH, LT also binds NXPH.  These interactions lead us to question whether 
recombinant NXPH1 would affect the observed effect of LT in vitro.  We observed that 
the pro-survival effect of LT is blocked by the addition of recombinant NXPH1 (Figure 
11B).  Because these studies were conducted in a population of cells, we were curious 
whether endogenous DAG1 played a role.  Rather than examine the effect of LT on 
individually plated CD34+ cells, GM-CSF+SCF was used as a proxy culture condition 
where the effect of endogenous DAG1 is not observed.  Alpha-latrotoxin does not affect 
recombinant NXPH1-mediated inhibition in cells treated with GM-CSF+SCF (Figure 12A) 
nor do growth factor starved cells behave differently when exposed to GM-CSF+SCF 
(Figure 12B).  Intriguingly, LT does not appear to increase survival of cells treated with 
IL-3 or IL-3+SCF after delayed growth factor addition. 
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Figure 10: 
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Figure 10: Recombinant NXPH1 does not affect ex vivo expansion of huCB CD34+ cells. 
 
MACS separated huCB CD34+ cells were expanded ex vivo in 50ng/ml SCF, 100ng/ml 
TPO, and 100ng/ml Flt3L (STF) in the presence or absence of 200ng/ml NXPH1 for three 
days.  Cells were then stained for CD34+ and analyzed. 
 
Top:  Fold expansion of CD34+ cells after three days of expansion in the presence and 
absence of 200ng/ml recombinant NXPH1.  (3 combined independent experiments; 
mean±SD). 
 
Bottom:  Percent of wells containing individually plated expanded huCB CD34+ cells 
producing CFU-GM, BFU-E, and CFU-GEMM colonies in the presence of recombinant 
NXPH1 (252 wells were evaluated for each point; mean±SD). 
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Figure 11: 
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Figure 11:  Alpha-latrotoxin has a pro-survival effect on growth-factor starved HPCs. 
 
A:  Percent increase in survival of huCB HPCs plated with either 200ng/ml SDF1α or 
varying concentrations of alpha-latrotoxin (LT) under delayed growth-factor addition for 
24 or 48 hours (3 combined independent experiments each performed in triplicate; 
mean±SD). 
 
B:  Percent increase in survival of huCB cells plated with either 50nm LT, 200ng NXPH1, 
50nm LT and 200ng NXHP1 or PBS control.  After a 24 hour growth factor starvation, 
GM-CSF, IL-3, Epo, and SCF were added to the experimental and control plates (3 
combined independent experiments each performed in triplicate; mean±SD). 
 
*p<0.05  
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Figure 12:  
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Figure 12:  Recombinant NXPH1 blocks the pro-survival effect of LT  
 
A:  Percent inhibition of huCB cells plated with 50nm LT and/or 200ng NXPH1 and 
various growth factors (2 combined independent experiments each performed in 
triplicate; mean±SD). 
 
B:  Percent increase in survival of huCB cells plated with 50nm LT and/or 200ng NXPH1.  
After a 24 hour growth factor starvation, the growth factors shown were added to the 
experimental and control plates (2 combined independent experiments each performed 
in triplicate; mean±SD). 
 
*p<0.05 
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Expression of DAG1, NRXN1α and NXPH1 in the murine hematopoietic system 
 
We observed interesting similarities and differences between the huCB and the murine 
hematopoietic system.  The pattern of NRXN1α expression in adult muBM mirrors that 
found in huCB with a higher percentage of primitive cells expressing NRXN1α while a 
high percentage of many populations express DAG1, particularly lymphoid progenitors 
(Table 2).  Because NRXN1α expression correlates with a primitive hematopoietic 
phenotype and DAG1 has been implicated in the hematopoietic niche (Hines, Nielsen et 
al. 2008), we examined the expression pattern of NRXN1α and DAG1 in the bone 
marrow using immunohistochemistry.  DAG1 is clearly expressed on active osteoblasts 
within the bone marrow (Figure 13).  Cells expressing high levels of NRXN1α in the bone 
marrow appear in close proximity with cells expressing DAG1, including stromal cells 
near the osteoblasts.  NXPH is not found at concentrations above background in muBM 
cells and mu peripheral blood plasma; however previous studies have implicated NXPH 
in the spleen.  Since NXPH is secreted, intracellular staining was used to examine which 
populations within the spleen express NXPH.  A small percent of splenocytes (5.2±0.3%) 
appear to express NXPH, with the majority of the expression confined to the lineage 
positive fraction (7.8±1.0% positive for NXPH).  A small percentage of CMPs in the 
spleen (3.4±0.7%) also contained NXPH.  
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Table 2: 
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Table 2:  Expression of NRXN1α and DAG1 in murine bone marrow. 
 
The expression of NRXN1α and DAG1 on stem and progenitor populations within the 
muBM.  Populations are defined as: long-term repopulating HSCs (LTR-HSC; lineage-, 
sca-1+, c-kit+, IL-7Rα-, CD34-), short-term repopulating HSCs (STR-HSC; lineage-, sca-1+, c-
kit+, IL-7Rα-, CD34+) common lymphoid progenitor (CLP; lineage-, sca1+, c-kit+, IL-7Rα+), 
megakaryocyte/erythroid progenitor (MEP; lineage-, sca1-, c-kit+, CD34-, FcγR-/lo), 
common myeloid progenitor (CMP; lineage- sca1-, c-kit+, CD34+, FcγR-/lo), and 
granulocyte/macrophage progenitor (GMP; lineage-, sca1-, c-kit+, CD34+, FcγR+/hi).  Data 
was collected from samples using an LSR II (BD) instrument and BD FACSDiva software 
and analyzed using WinList software. 
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Figure 13: 
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Figure 13:  DAG1 and NRXN1α co-localize near osteoblasts in muBM.   
 
Low (20x) and higher (40x) power microphotographs of serial sections mounted using 
Permount mounting medium and stained with hematoxylin and eosin (H&E) or anti-α-
DAG1, anti-NRXN1α, rabbit IgG isotype antibodies.  DAG1 and NRXN1α co-localized to 
active osteoblasts (marked with an arrow).  Immunoreactivity was also observed along 
the periphery of megakaryocytes and erythrocytes for both DAG1 and NRXN1α.  Note 
the lack of immunoreactivity in osteocytes and stromal cells.  Micrographs were taken 
on a Leica BM3000 microscope with PLAN objective x20 (NA 0.4) or a PLAN objective 
x40 (NA 0.65) at room temperature.  Images were captured using Leica Application Suite 
v3.6.0 from Leico Microsystems. 
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GM-CSF maintains NRXN1α expression in muBM cells 
 
In vitro exposure of muBM cells plated together with recombinant NXPH1 (Figure 14) 
mirrors results found in huCB cells.  However, NRXN1α is expressed at a high enough 
level in muBM to be detected by Western analysis, which provided us with a powerful 
tool to investigate the effect of recombinant NXPH1 on cells stimulated by GM-CSF+SCF.  
Freshly harvested muBM cells were cultured under a variety of growth conditions for 24 
hours and the expression of NRXN1α was examined (Figure 15).  NRXN1α is apparent in 
freshly isolated cells but when cultured with SCF, IL-3 and IL-3+SCF, expression level 
decreases significantly.  However, expression of NRXN1α is maintained in cells cultured 
with either GM-CSF or GM-CSF+SCF.  As DAG1 is less expressed on mature cells (Figure 
3, Figure 13, Table 2), we considered that the ratio of NRXN1α to DAG1 may be altered 
in favor of available NRXN1α.  If true, cells plated in a population would require a higher 
concentration of recombinant NXPH1 in order for equivalent levels of inhibition to be 
observed.  Human CB and muBM cells respond similarly to recombinant NXPH1 in 
population with maximal inhibition observed at 500ng/ml.  However, individually plated 
human CD34+ huCB cells reach their maximal inhibition at 200ng/ml.  An examination of 
the dose-response curves (Figure 16) reveals that the affinity of NXPH1 to NRXN1α on 
individually plated CD34+ cells (IC50=68.8±5.9ng/ml) is the same as for NXPH1 to 
NRXN1α on huCB and muBM cells plated in a population (IC50=68.7±1.8ng/ml and 
71.0±4.8ng/ml, respectively). 
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Figure 14: 
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Figure 14:  Recombinant NXPH1 selectively inhibits proliferation stimulated by GM-
CSF+SCF in muBM cells in vitro. 
 
Percent recombinant NXPH1-mediated inhibition of CFU-GM colony formation in 
primary muBM cells plated as a population under a variety of factor-stimulated growth 
conditions (3 combined independent experiments, each done in triplicate; mean±SD) 
***p<0.0005 
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Figure 15: 
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Figure 15: Expression of NRXN1α is maintained by GM-CSF and downregulated by IL-3. 
 
Top:  Representative Western blot of lysate from primary muBM cells cultured for 24 
hours under a variety of conditions.  The first lane represents lysate from freshly 
harvested muBM.  β-actin is shown as a loading control.  
 
Bottom:  Densitometric analysis of NRXN1α expression in Western blots.  Values were 
normalized to β-actin and represented as a percent of the Day 0 control (4 combined 
independent experiments; mean±SD). 
*p<0.05 
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Figure 16: 
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Figure 16:  DAG1 is an allosteric inhibitor of NXPH1 function. 
 
Calculated dose-response curves modeling the NXPH1-mediated inhibition of CFU-GM 
colony formation in the presence of GM-CSF+SCF.  HPCs were derived from either 
individually plated huCB CD34+ (R2=0.95), huCB plated in population (1x104cells/ml) 
(R2=0.99), or muBM plated in population (5x104cells/ml) (R2=0.99) (288 wells were 
evaluated for each data point in experiments involving a single plated cell; at least three 
independent experiments performed in triplicate were used for calculating data points 
involving cells plated in a population; mean±SD).  
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However, the efficacy of NXPH1 on individually plated CD34+ (Imax=68.7±2.7 % 
inhibition) is much greater than when huCB and muBM cells are plated in a population 
(Imax=40.7±3.3 and 43.7±2.5 % inhibition, respectively).  From this we conclude that 
DAG1 decreases the efficacy of NXPH1 but not its affinity, suggesting that DAG1 is a 
non-competitive agonist.  Non-competitive antagonism coupled with the knowledge 
that DAG1 and NXPH1 bind different areas within the second LNS domain of NRXN1α 
(Lise and El-Husseini 2006) strongly suggests that an allosteric interaction is at play.  
While the inhibitory effect of blocking DAG1 on GM-CSF+SCF (Figures 5 and 14) 
complicates these findings and demands that other factors are present, we feel these 
findings help explain the particular effect of recombinant NXPH1 on cells treated with 
GM-CSF+SCF.  Additionally, the near-absolute downregulation of NRXN1α in growth 
conditions containing IL-3 helps explain the inability of LT to promote survival in cells 
treated with IL-3 or IL-3+SCF. 
 
Recombinant NXPH1 exhibits suppressive effects in vivo 
 
To determine the effect of recombinant NXPH1 on the hematopoietic system in vivo, 
normal C57Bl/6 mice were injected i.v. with endotoxin-free recombinant NXPH1.  
Twenty-four to 48 hours after injection of  recombinant NXPH1, the total number of 
circulating leukocytes, as well as neutrophils, lymphocytes, monocytes, basophils and 
platelets were significantly decreased (Figure 17).   
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Figure 17:  In vivo injection of NXPH1 decreases the absolute number of many mature 
hematopoietic populations in mouse peripheral blood. 
 
Change in peripheral blood populations after i.v. injection of recombinant NXPH1 
expressed as a percentage of control (at least three independent experiments 
performed in triplicate; mean±SD).   
 
*p<0.05, **p<0.005, ***p<0.0005. 
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Absolute numbers and cycling status of HPCs in the BM were decreased in a dose- and 
time-dependent manner (Figure 18 and 19, respectively).  At a maximally inhibitory dose 
(2.5-5µg NXPH1/mouse), absolute numbers of HPCs were inhibited by 50.8% at 24 
hours, effects mirrored by decreases at 24 hours in cycling HPCs (measured by high 
specificity activated tritiated thymidine kill assay).  After 48 hours, absolute numbers of 
HPCs were increased but still significantly inhibited: HPC numbers completely returned 
to normal levels 72 hours after injection of NXPH1, a trend mirrored in the cycling status 
of BM HPCs.  Consistent with functional data, phenotypically defined BM HPCs were also 
suppressed by recombinant NXPH1 (Figure 20) at levels similar to those observed in 
functional assays.  In contrast to the BM, the spleen was less responsive to NXPH1 
exposure.  At a maximally inhibitory dose (5µg NXPH1/mouse) absolute numbers of 
splenic HPCs were unaffected for the first two days and increased slightly after the third 
day (Figure 21A).  The cycling status of splenic HPCs was decreased 24 hours after 
injection but returned to baseline after 48 hours, and was slightly increased after 72 
hours (Figure 21B). 
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Figure 18: 
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Figure 18:  Recombinant NXPH1 decreases the absolute number and cycling status of 
muBM HPCs in a dose-dependent manner. 
 
A:  Absolute colony number of muBM-derived HPCs 24-hours after exposure to varying 
doses of recombinant NXPH1 (combined data of three independent experiments each 
performed in triplicate; mean±SD).   
 
B:  Cycling status of muBM-derived HPCs 24-hours after exposure to varying doses of 
recombinant NXPH1 (combined data of three independent experiments each performed 
in triplicate; mean±SD). 
 
*p<0.05, **p<0.005, ***p<0.0005.  
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Figure 19: 
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Figure 19: Recombinant NXPH1 decreases the absolute number and cycling status of 
muBM HPCs in a time-dependent manner. 
 
A:  Absolute colony number of muBM-derived HPCs 24, 48, and 72 hours after exposure 
to DPBS carrier or 5µg/mouse NXPH1 (combined data of three independent 
experiments each performed in triplicate; mean±SD).   
 
B:  Cycling status of muBM-derived HPCs 24, 48, and 72 hours after exposure to DPBS 
carrier or 5µg/mouse NXPH1 (combined data of three independent experiments each 
performed in triplicate; mean±SD). 
 
*p<0.05, **p<0.005 
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Figure 20: 
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Figure 20:  Recombinant NXPH1 decreases phenotypically-defined progenitor cells in a 
time dependent manner. 
 
Change in phenotypically defined progenitor populations 24 hours after intravenous 
exposure to DPBS carrier or 5µg/mouse NXPH1 expressed as a percent control 
(combined data of three independent experiments each performed in triplicate; 
mean±SD). 
 
*p<0.05, **p<0.005. 
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Figure 21:  
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Figure 21:  Recombinant NXPH1 has fewer effects on splenic HPCs in vivo. 
 
A:  Absolute colony number of spleen-derived HPCs 24, 48, and 72 hours after exposure 
to DPBS carrier or 5µg/mouse NXPH1 (combined data of three independent experiments 
each performed in triplicate; mean±SD).   
 
B:  Cycling status of spleen-derived HPCs 24, 48, and 72 hours after exposure to DPBS 
carrier or 5µg/mouse NXPH1 (combined data of three independent experiments each 
performed in triplicate; mean±SD).   
 
*p<0.05 
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Primitive HSCs are bound to DAG1 in vivo 
 
To determine effects of NXPH on functional HSCs, C57Bl/6 mice (CD45.2+) were 
intravenously injected with either 5µg recombinant NXPH1 or DPBS carrier.  Bone 
marrow was collected from these treated mice after 24 hours, and these cells combined 
at equal cell numbers with untreated competitor BM cells from BoyJ mice (CD45.1+).  
Lethally irradiated C57/BoyJ F1 mice had their hematopoietic system reconstituted 
using these cells.  Donor cells from NXPH1-treated mice manifested significantly 
decreased short-term repopulation potential, balanced by a transient increased in 
intermediate repopulation potential (Figure 22).  After seven months, no effect on long 
term competitive repopulation potential was observed during the primary transplant 
(Figure 23A).  To further characterize the effect of NXPH1 on the LTR-HSC compartment, 
2x106 total BM cells from the primary recipients were transfused into a second set of 
lethally irradiated C57/BoyJ F1 mice.  After four months, the secondary recipients were 
sacrificed and the percent chimerism in the total BM as well as specific lineage 
populations was examined (Figure 23B).  Consistent with the data from month seven of 
the primary transplant, no difference was found between the experimental condition 
and control.  This suggested that NXPH1 does not have an effect on the long-term 
repopulating potential of primitive HSCs. 
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Figure 22: 
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Figure 22:  Pre-treatment of donor animals with recombinant NXPH1 has different 
effects on STR- ITR- and LTR-HSCs. 
 
Peripheral blood chimerism of donor cells derived BM from pool of 3 mice per 
treatment group combined with BoyJ competitor cells 24 hours after treatment of mice 
with DPBS carrier or 5µg/mouse recombinant NXPH1 transplanted into 5 treatment 
groups. (mean±SD). 
 
A:  1:1 competitor:donor cell ratio 
B:  0.5:1 competitor:donor cell ratio 
 
*p<0.05, **p<0.005. 
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Figure 23: 
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Figure 23:  Pre-treatment of donor mice with recombinant NXPH1 does not affect long-
term engraftment. 
 
A:  Percent chimerism of donor cells in total BM, as well as several lineage restricted 
populations in primary recipients after seven months.  In the competitive repopulation 
assay, pooled BM from 3 C57Bl/6 mice per treatment group was combined either 1:1 or 
0.5:1 with BoyJ competitor cells 24 hours after treatment of mice with DPBS carrier or 
5µg/mouse recombinant NXPH1 and transplanted into 5 mice per treatment group 
(mean±SD).   
 
B:  Percent chimerism in total BM, as well as several lineage restricted populations in 
secondary recipients derived from either 1:1 or 0.5:1 primary competitive repopulation 
assay. After seven months, 5 secondary recipients per treatment group were transfused 
with pooled BM from at least 4 members of the corresponding primary transplant 
group.  Four months after the secondary transplant, BM was harvested and analyzed for 
percent chimerism was analyzed (mean±SD). 
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We had demonstrated using single cell culture and DAG1 blocking antibodies that DAG1 
counteracts the suppressive effects of NXPH1 on HPCs in vitro.  As absolute numbers of 
femoral HPCs are suppressed by in vivo administration of NXPH1 while the long-term 
repopulating potential of primitive HSCs was unaffected, we hypothesized that only 
primitive HSCs are bound to DAG1 in vivo.  To test this, muBM cells harvested from 
control and NXPH1-treated mice were treated with DAG1 blocking antibody prior to in 
vitro culture in presence of NXPH1.  If HPCs were influenced by DAG1 in vivo, HPCs 
removed from mice exposed to NXPH1 in vivo ought to be further inhibited by anti-
DAG1+NXPH1 in vitro.  Conversely, if HPCs are not influenced by DAG1 in vivo, in vitro 
exposure to anti-DAG1+NXPH1 ought not be inhibitory, due possibly to either maximal 
inhibition or receptor down-regulation.  We found no further inhibition of HPCs after in 
vitro exposure to anti-DAG1+NXPH1, supporting the hypothesis that HPCs are not likely 
influenced by DAG1 in vivo (Figure 24).   
 
To determine which populations were affected by NXPH1 in vivo, phenotypically-defined 
BM HSCs/HPCs were examined 24 and 48 hours after mice were injected i.v. with 
recombinant NXPH1.  Consistent with HPC data, STR-HSCs were suppressed at both 
time-points.  Cells categorized in the longer-term population of HSCs experienced 
significant increase in numbers after 24 hours, but had returned to base-line after 48 
hours (Figure 25). 
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Figure 24: 
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Figure 24:  Murine BM HPCs are not exposed to DAG1 in vivo. 
 
Effect of in vitro exposure to recombinant NXPH1 on muBM total CFUs derived from 
mice treated with recombinant NXPH1 in vivo.  Mice were i.v. injected with either DPBS 
carrier or 5µg recombinant NXPH1.  Twenty-four hours after in vivo exposure, BM was 
harvested and treated with either mouse IgM or anti-DAG1 blocking antibody in vitro 
and then plated in SCF, GM-CSF, PWMSCM and Epo ± 200ng/ml recombinant NXPH1 
(combined data of three animals each analyzed in triplicate; mean±SD). 
 
**p<0.005  
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Figure 25: 
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Figure 25:  Absolute numbers of primitive HSCs are transiently increased in mice 
exposed to recombinant NXPH1 in vivo. 
 
Fold change in vivo of phenotypically-defined HSCs 24 and 48 hours after injection of 
5µg/mouse recombinant NXPH1 (combined data from two independent experiments 
performed in triplicate; mean±SD). 
 
**p<0.005 
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To further investigate this, normal C57Bl/6 mice underwent the same injection 
procedure, but with addition of BrdU.  BrdU was co-injected with recombinant NXPH1 
and placed in drinking water after mouse exposure to NXPH1.  Twenty-four hours after 
exposure of mice to NXPH1 or control media, BM cells from treated and untreated mice 
were sorted into: KSL CD34- (c-kit+, sca1+, lineage- CD34lo/-) and KSL CD34+ cells.  
Mirroring functional and phenotypic data, KSL CD34+ cells experienced a 38% decrease 
in percentage of cells in S-phase, while KSL CD34- cells from NXPH1-treated mice had a 
3.7 fold increase in cycling cells (Figure 26A).  In both conditions, the cells entering S-
phase appeared to come from cells in G1/G0 as a corresponding decrease in total 
percentage was observed in these populations suggesting cell-cycle arrest.  Because cell 
cycle arrest is often associated with apoptosis, we examined extracellular Annexin V 
expression on the phenotypically defined populations in treated and untreated mice; 
however no increase in apoptosis was observed in the treated mice (data not shown). 
     
There are two possible interpretations for increases in numbers and cycling status of 
phenotyped LTR-HSCs: either NXPH1 directly induces cycling, or cycling is perhaps 
induced to re-assert homeostasis challenged by inhibitory effects of NXPH1 on HPCs.  In 
the hematopoietic system, the mTOR pathway is involved in stress responses (Campbell, 
Basu et al. 2009) consistent with the second interpretation, so cycling status of both the 
LTR- and STR-HSCs was examined in mice treated in the same manner as above but with 
i.p. injection of Rapamycin or ethanol-carrier immediately prior to NXPH1 i.v. injection.  
Exposure of mice to Rapamycin inhibited increases in cycling of KSL CD34- cells while  
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Figure 26: 
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Figure 26:  The increase in primitive HSC in response to recombinant NXPH1 is 
homeostatic in nature. 
 
A:  Fold change in cycling status of populations heavily enriched for long (LSK CD34-) or 
short (LSK CD34+) term engrafting HSCs 24 hours after injection of 5µg/mouse 
recombinant NXPH1(combined data from two independent experiments performed in 
triplicate; mean±SD).   
 
B:  Fold change in phenotypically defined HSCs 24 hours after 5µg/mouse i.v. 
recombinant NXPH1 exposure and 5mg/mouse i.p. rapamycin injection (combined data 
from two independent experiments performed in triplicate; mean±SD).   
 
*p<0.05, **p<0.005 
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leaving KSL CD34+ cells unaffected (Figure 26B).  Because our results show that mTOR is 
at least partially involved in stimulation of LTR-HSCs in response to NXPH1 exposure in 
vivo, but is not involved in NXPH1-mediated inhibition of STR-HSCs, and because 
induction of the mTOR pathway in LTR-HSCs has been associated with a homeostatic 
stress response (Campbell, Basu et al. 2009), we believe that LTR-HSCs are not directly 
affected by NXPH1 and the observed increase in phenotypically defined HSCs is due to a 
homeostatic response mediated at least partially through the mTOR pathway. 
    
Results summary 
 
A signaling axis centered on the second LNS domain of NRXN1α is present and 
functional in the hematopoietic system.  High expression levels of NRXN1α and DAG1 
are found in primitive hematopoietic populations but not mature hematopoietic 
populations.  Therefore, expression of NRXN1α and DAG1 correlates with primitive 
hematopoietic populations in both huCB and muBM (Figure 3, Table 2) and NXPH is 
found in high concentrations in huCB plasma but not the plasma of adult humans or 
mice.  Having demonstrated their presence, the next step was to define their function in 
vitro and in vivo. 
 
In vitro, recombinant NXPH1 was shown to have a directly inhibitory effect on HPC 
proliferation (Figures 4-8, 14); however NXPH1 activity was allosterically inhibited by 
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endogenous DAG1 (Figure 16) thus, with one exception, NXPH1 inhibitory activity was 
observed on either individually plated cells (Figures 6-8) or cells exposed to anti-DAG1 
blocking antibodies (Figure 5).  The lone exception was the ability of NXPH1 to inhibit 
the proliferation of HPCs stimulated by GM-CSF+SCF which was observed under all 
conditions tested (Figures 4, 5, 7, 9, 12, 14).  Because GM-CSF maintains NRXN1α 
expression (Figure 15) and DAG1 expression decreases as cells differentiate (Figure 3), 
we hypothesize that the high degree of proliferation stimulated by GM-CSF+SCF alters 
the ratio of NRXN1α:DAG1 in such a manner as to allow NXPH1 to interact with some, 
though not all, HPCs and thereby elicit a significant degree of observed inhibition (Figure 
16).  The in vitro interaction between endogenous NRXN1α and DAG1 with recombinant 
NXPH1 is diagrammed in Figure 27A. 
 
Mirroring the in vitro results, in vivo exposure to recombinant NXPH1 has a suppressive 
effect on murine hematopoiesis.  NXPH1 decreased the absolute numbers of mature 
hematopoietic cells in the peripheral blood (Figure 17) as well as both the absolute 
numbers and cycling status of muBM HPCs (Figures 18-20) in a time- and dose-
dependent manner.  Intriguingly, the absolute number and cycling status of HSCs was 
increased after NXPH1 injection (Figures 25 and 26A).  Because endogenous DAG1 is 
able to antagonize NXPH1-mediated inhibition in vitro (Figure 5), we hypothesized that 
HSCs but not HPCs were bound to DAG1 in vivo and the observed increases were a 
homeostatic response.  The involvement of the mTOR pathway in the behavior of HSCs 
but not HPCs (Figure 26B) supports the hypothesis that response of HSCs to NXPH1 
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injection is homeostatic in nature.  Likewise, the inability of HPCs from mice injected 
with NXPH1 to be further inhibited by NXPH1 in vitro suggests that HPCs are not bound 
to DAG1 in vivo (Figures 23 and 24).  Immunohistochemistry further supports the 
hypothesis that HSCs are bound to DAG1 in vivo (Figure 13) where NRXN1α-expressing 
stromal cells are found in the vicinity of DAG1-expressing osteoblasts.  The in vivo 
interaction between endogenous NRXN1α and DAG1 with recombinant NXPH1 is 
diagrammed in Figure 27B. 
 
The characterization of a heretofore unrecognized signaling axis in the hematopoietic 
system has a variety of implications which should be considered. 
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Figure 27: 
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Figure 27:  Diagrammatic role of NRXN1α, DAG1, and NXPH1 in the hematopoietic 
system. 
 
A:  NRXN1α, DAG1 and recombinant NXPH1 as they behave in the hematopoietic model 
in vitro.   
 
B:  Hypothetical interaction of NRXN1α, DAG1 and recombinant NXPH1 in vivo. 
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Discussion 
 
A signaling axis centered on the second LNS domain of NRXN1α is present and 
functional in the hematopoietic system.  Expression of NRXN1α correlates with primitive 
hematopoietic populations, while DAG1 is heavily expressed on active osteoblasts in the 
bone marrow and is also present on many hematopoietic cells.  The third member of the 
axis, the NXPH family, is found in huCB plasma and within lineage positive cells in the 
mouse spleen.  We found that recombinant NXPH1 acts as a potent inhibitor of HPC 
proliferation in vivo and in vitro; however this inhibition is allosterically inhibited by the 
presence of DAG1.  We suggest that NXPH directly acts to suppress hematopoiesis, and 
a role of DAG1 is to occupy NRXN1α, thereby preventing excess inhibition. 
 
Physiological role of the NRXN1α axis in hematopoiesis 
 
The role of this axis in healthy animals remains unclear; however, human disease 
models involving disrupted members of this signaling axis and a hematopoietic 
phenotype may provide insight.  While the precise cause of schizophrenia in humans 
remains unknown one, of four conditions usually applies: disruption of NRXN1 (Kirov et 
al., 2008), disruption of Lin2 (Kristiansen, Beneyto et al. 2006)− the protein directly 
downstream of NRXN1, over-expression of IL-3 (Chen, Wang et al. 2007; Xiu, Chen et al. 
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2008), or an overactive IL-3R (Chen, Wang et al. 2007; Lencz, Morgan et al. 2007; Sun, 
Wang et al. 2008; Sun, Wei et al. 2009).  We have shown that IL-3 downregulates 
NRXN1α expression in vitro, so it seems reasonable to suggest that under conditions 
pertaining to schizophrenia, NRXN1α is either absent or non-functional.  Schizophrenics 
have a higher number of leukocytes, especially monocytes and neutrophils as compared 
to normal individuals (Wilke, Arolt et al. 1996).  While the lymphocyte levels remain 
normal, a higher percentage of them are in S-phase (Malacarne and Dallapiccola 1969) 
and they have an abnormal ratio between T-helper types 1 and 2 (Wilke, Arolt et al. 
1996; Monji, Kato et al. 2009).  This hematopoietic phenotype resembles the 
hematopoietic phenotype of autistics, so the relevance of both autism and 
schizophrenia to the research presented in this thesis will be presented together after 
the hematopoietic phenotype of autism has been described.. 
 
NRXN1α also appears to play an important role in autism spectrum disorder, as ultra-
rare cohorts of particular missense mutations and splice variants have been associated 
with the disease (Kim, Kishikawa et al. 2008; Glessner, Wang et al. 2009); disruption of 
NRXN1α due to chromosomal breakage has also been linked to autism (Kim, Kishikawa 
et al. 2008).  Interestingly, the chromosomal breakage that disrupted NRXN1α appeared 
to leave NRXN1β unaffected and while some correlation between specific missense 
mutations in NRXN1β and autism have been suggested (Feng, Schroer et al. 2006; Kim, 
Kishikawa et al. 2008); however family data suggests that incomplete penetrance occurs 
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(Yan, Noltner et al. 2008).  Similar to schizophrenia, autism is associated with high 
monocyte counts; additionally, autistics have an abnormal CD4:CD8 T-cell ratio 
(Sweeten, Posey et al. 2003).   
 
The hematopoietic phenotypes of schizophrenics and autistic neatly mirrors that of mice 
intravenously injected with NXPH1.  Schizophrenics and autistics exhibit increased 
numbers and cycling status of many hematopoietic populations; whereas mice 
intravenously injected with NXPH1 have both a decreased total leukocyte number and a 
higher percentage of non-cycling progenitors.  The absence of the inhibitory effect of 
NXPH1 in schizophrenics and autistics due to the absence of its receptor could explain 
the myeloid phenotype.  The explanatory power of this model in the lymphoid 
compartment is weaker, as one would expect a higher number of lymphoid cells in 
patients with these diseases based off the mouse data (Coffman and Weissman 1981; 
Muller, Riedel et al. 2000; Monji, Kato et al. 2009; Stefansson, Ophoff et al. 2009; 
Enstrom, Onore et al. 2010).  While the expected phenotype is not observed, both 
diseases are strongly pro-inflammatory.  The hematopoietic exuberance of these 
diseases coupled with the inhibitory effect of recombinant NXPH1 injected in vivo 
argues in favor of the hypothesis that the primary role of this axis is to suppress 
hematopoiesis. 
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The question is whether the observed inhibition is due to presence of recombinant 
NXPH1 or to absence of DAG1 on cells expressing NRXN1α.  Previous work in the 
neuronal system (Sugita, Saito et al. 2001) as well as the similar behavior between 
recombinant NXPH1 and DAG1-blocking antibodies on cells exposed to GM-CSF+SCF 
favor the former interpretation.  However, there are problems with this model.  Were 
DAG1 required for survival, one would expect to observe a decrease in the colony 
forming ability of individually plated progenitors and progenitors exposed to anti-DAG1 
blocking antibody.  With the exception of the aforementioned GM-CSF+SCF condition, a 
decrease is not observed.  Additionally, DAG1 is widely expressed in a variety of tissues 
in vivo, yet in vivo administration of NXPH exhibits an inhibitory effect consistent with in 
vitro data arguing that HPCs are not bound to DAG1 in vivo.  Lastly, recombinant NXPH1 
cannot bind NRXN1α in the presence of DAG1 due to non-competitive antagonism 
making it extremely unlikely that NXPH could disrupt the DAG1-NRXN1α bond.  Taken 
together with the hematopoietic phenotypes of schizophrenia and autism, this data 
argues that the NRXN1α axis is suppressive in nature and that NXPH binding inhibits 
proliferation.   
 
A most interesting member of this signaling axis may be the NXPH-family, particularly 
NXPH1.  When injected in vivo recombinant NXPH1 acts in a myelo- and 
lymphosuppressive manner, decreasing absolute numbers and cycling status of 
muHPCs, as well as circulating populations of more mature hematopoietic cells.  In 
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contrast, absolute numbers and cycling status of phenotypically defined HSCs was 
increased after recombinant NXPH1 administration.  The rapamycin sensitive nature of 
these increases suggests that HSCs are not directly induced by NXPH1, and the increase 
may be a homeostatic response to replenish the affected populations below in the 
hematopoietic hierarchy.  Since many populations downstream in the hematopoietic 
hierarchy are affected by recombinant NXPH1 administration, unaffected upstream 
populations are called upon to maintain homeostasis and transiently leave their 
quiescent state.  The absolute numbers of phenotypically defined HSCs are increased 
after 24 hours and have returned to baseline after 48 hours.  The absolute numbers of 
functionally defined HPCs are greatly reduced after 24 hours, slightly depressed after 48 
hours, and fully recovered after 72 hours.  In light of the hematopoietic hierarchy where 
a small number of primitive cells differentiate into a large number of mature cells, the 
transient nature of this increase coupled with a restoration of normal BM HPC 
populations shortly thereafter argues in favor of a homeostatic response.  Transplant 
engraftment studies in which competitive repopulation ability of BM cells taken from 
NXPH1-treated mice is only transiently effected suggest that the true LTR-HSC 
compartment may be unaffected by the increase observed within the phenotypically 
defined population.  Another interpretation of the data consistent would be that an as-
of-yet unrecognized population of HS/PCs transiently adopts a set of 
immunohistological markers similar to LTR-HSCs as they respond to a hematopoietic 
challenge.  Either way, these results suggest that LTR-HSCs may exist in a privileged 
state, unaffected by NXPH1.  Since NRXN1α is present at the cell surface of 
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phenotypically-defined LTR-HSCs, this privileged state may reflect two scenarios: either 
NXPH1 binds NRXN1α and the message is not conveyed due to downstream elements or 
NXPH1 cannot bind NRXN1α.  The in vitro antagonism of DAG1 on NXPH1-mediated 
inhibition may shed light on which of these interpretations better model the system.  
With the exception of GM-CSF+SCF, the presence of endogenous DAG1 is sufficient to 
prevent NXPH1-mediated inhibition in vitro.  Furthermore, the efficacy of NXPH1 in vivo 
(Imax=58.2±4.5 % inhibition) is significantly greater than with GM-CSF+SCF in vitro 
(Imax=43.7±2.5 % inhibition).  The activity of HPCs exposed to NXPH1 in vivo most closely 
resemble HPCs exposed to NXPH1 in the absence of DAG1 in vitro.  In contrast, 
phenotypically-defined HSCs are not inhibited by in vivo administration of NXPH1; 
instead they proliferate in what may be a homeostatic response.  While indirect 
elements are almost certain, we feel that it is reasonable to hypothesize that primitive 
HSCs may be bound to DAG1 in the niche, whereas less primitive HSCs and HPCs tend 
not to be bound to DAG1 in vivo.  This hypothesis is supported by the high expression 
level of DAG1 on active osteoblasts coupled with the close proximity of NRXN1α 
expressing hematopoietic stromal cells in the BM to DAG1 expressing osteoblasts.  From 
this we propose a model (diagrammed in Figure 27), suggesting that the role of DAG1 in 
hematopoiesis is to “protect” primitive hematopoietic cells from exposure to members 
of the NXPH-family. 
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The next question is to what end this protection and inhibition serve.  Under normal 
conditions the only hematopoietic tissues where NXPH-family members were identified 
are the spleen and umbilical CB.  Both of these tissues have a relatively quiescent 
hematopoietic compartment and their HPCs exhibit a low level of cycling.  This 
phenotype is consistent with the observed effects of recombinant NXPH1.  These data 
suggest that NXPH plays a role in maintaining the quiescent nature of HPCs in these 
tissues.  If NXPH is involved in suppressing the proliferation of hematopoietic cells in the 
spleen, it would be necessary for this effect to be reversible during extramedullary 
hematopoiesis.  An interesting candidate for this role is IL-3.  A pro-inflammatory 
cytokine, IL-3 is expressed during periods of hematopoietic stress such as would precede 
extramedullary hematopoiesis in the spleen.  Additionally, splenic cells induced to 
proliferate by pokeweed mitogen produce high levels of IL-3.  As IL-3 downregulates 
NRXN1α, HPCs would be unable to respond to NXPH and thus proliferate.   
 
Another potential explanation would be survival-dependent selection of primitive 
hematopoietic cells.  It is intuitively appealing to think that in the initial stages of life 
HSCs undergo a strong selective process thereby protecting the organism against variety 
of potential hematopoietic disorders.  If life-long, true, HSCs do originate in the 
placenta, the umbilical cord might be the location of this selection.  Likewise, splenic 
HSCs remain quiescent until called upon in extreme situations.  While the specifics of 
the challenge that awakens splenic HS/PCs are varied, the desperate nature of 
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extramedullary hematopoiesis may demand a similar selective process.  This thesis 
provides no conclusive data in favor of this hypothesis; however, DAG1 has been shown 
to play a role in the positive selection of T-cells (Zhang, Wang et al. 2006), so any 
interpretation dismissing the potentially selective role of the NRXN1α axis in 
hematopoiesis is premature. 
 
Of particular interest is the relationship between NXPH and huCB.  Unlike 
myelosuppressive chemokines (Lu, Xiao et al. 1993), recombinant NXPH1 is able to 
suppress the colony forming ability of HPCs from freshly isolated huCB.  Additionally, we 
found high concentrations of NXPH-family members in huCB plasma, but not in adult 
human and murine peripheral blood.  Taken together, these findings may be of some 
meaning in the context of huCB transplantation.  While offering many advantages as 
compared to other sources of HSCs, reconstitution time is longer in patients who have 
received huCB transplants.  It is possible, but not yet determined that members of the 
NXPH-family may play a role in the engraftment time of huCB cells in a clinical context. 
 
Which cells produce NXPH in the spleen and umbilical CB remains unknown.  Microarray 
data from other laboratories present macrophages as a potential candidate (Rodriguez, 
Chang et al. 2004).  This does not contradict our finding significant intracellular 
expression of NXPH in the lineage positive fraction of splenocytes as well as splenic 
CMPs.  If true, macrophages as a source of NXPH may be of relevance to the 
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hematopoietic niche (Chow, Lucas et al. 2011), a possibility whose relevance will be 
further detailed in future sections. 
 
Thus, the role of the NRXN1α axis in hematopoiesis appears to be suppressive.  The 
inhibitory effect of recombinant NXPH1 on HPC proliferation both in vivo and in vitro 
coupled with the high proliferation and pro-inflammatory phenotype of diseases where 
NRXN1α is absent argues that the primary actor in this axis is the NXPH-family.  The 
other ligand, DAG1, does not have an effect of its own; rather it serves as an 
endogenous antagonist of NXPH-mediated inhibition.  The suppressive effect of NXPH 
serves to maintain the quiescent state of HPCs in tissues such as cord blood and the 
spleen.  In the spleen, NXPH keeps HPCs in reserve until such a time when they are 
needed when they are activated by IL-3. 
 
The role of the NRXN1α axis in the hematopoietic niche 
 
In contrast to umbilical cord blood and the spleen, members of the NXPH family were 
not identified in the bone marrow compartment.  However, the expression of DAG1 on 
active osteoblasts coupled with the potential co-localization of NRXN1α-expressing cells 
to that site may have interesting implications for the hematopoietic niche.  While active 
osteoblasts do not mark the true hematopoietic niche, important information on the 
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true niche can be garnered from the osteoblastic niche (Mendez-Ferrer, Michurina et al. 
2010; Chow, Lucas et al. 2011).  In this case, the localization of phenotypically primitive 
hematopoietic cells to osteoblasts suggests that DAG1-NRXN1α interaction may play a 
role in niche function.   
 
In the neuronal system, NRXN1 serves as a mediator between GABAergic and adrenergic 
signaling and is involved in the formation of the GABAergic synapse.  The implications of 
NRXN1α as a mediator between GABAergic and adrenergic signaling are great when the 
nature of the true hematopoietic niche is considered.  In the true bone marrow niche, 
HSC activity hinges on an MSC and a beta-adrenergic neuron, with an osteoblast and a 
macrophage serving as intermediaries.  As noted previously, MSCs bear a great deal of 
similarity to post-synaptic GABAergic neurons and are able to compliment them in brain 
damaged mice.  In the hematopoietic system, GABA functions as a chemoattractant and 
cell cycle inhibitor for primitive hematopoietic cells, likewise it inhibits the activity of 
known mobilizing agents such as SDF1α.  These properties describe aspects of what one 
would expect to find in the hematopoietic niche: an attractant for homing, a cell cycle 
inhibitor to keep HSCs in a quiescent state, and an inhibitor of mobilization to keep cells 
within the niche.  However, in order for HSCs to function in a dynamic system HSCs must 
also be able to leave the niche and proliferate, both of which are induced by adrenergic 
signaling.  This creates the opportunity for a multifaceted system.  In this system, 
NRXN1α present on the HSC is able to mediate between the GABAergic MSC and beta-
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adrenergic neuronal signaling, thereby providing a bridge between properties necessary 
for HSC maintenance and maintenance of a functional hematopoietic system.  This 
network is further refined by DAG1 expressed on the osteoblast, which serves a 
scaffolding function maintaining the HSC in place so that it can mediate between 
excitatory and inhibitory signaling.  Lastly, the NXPH-secreting macrophage is able to 
keep the system in check by inducing a quiescent state in precocious HSCs.  While highly 
speculative, this model is presented as a vehicle for future discovery. 
 
For example, the instructive role of NRXN1 in GABAergic synapse development may be 
of relevance to the niche.  Because the bone marrow niche is not the site of 
hematogenesis, during development HSCs must migrate to the bone marrow niche 
where a hematopoietic synapse is formed between an HSC, an MSC, an osteoblast, as 
well as a beta-adrenergic neuron and a macrophage.  In the neuronal system, activation 
of NRXN1 is sufficient for GABAergic synapse development.  The cell expressing NRXN1 
will differentiate into the pre-synaptic cell while the other will differentiate into the 
post-synaptic cell.  The resemblance of MSCs to post-synaptic GABAergic neurons 
creates the exciting possibility that NRXN1 on HSCs plays an important role in the 
creation of the hematopoietic synapse.  If true, NRXN1 present on freshly generated 
HSCs could induce MSCs to produce part of the niche environment.  This would also help 
explain the similarities between niche MSCs and GABAergic neurons as their 
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development is instructed by the same signaling axis.  Furthermore, DAG1 expressed on 
the osteoblast may serve a scaffolding function, helping recruit the necessary factors. 
 
Our results present the possibility that the NRXN1α axis may be important in the 
hematopoietic niche.  Expression of NRXN1α on hematopoietic cells correlates with a 
primitive phenotype.  In the bone marrow stroma, cells expressing NRXN1α are in close 
proximity to active osteoblasts expressing DAG1.  While we recognize that osteoblasts 
are an imperfect model for the true hematopoietic niche, these results present the 
possibility that DAG1-NRXN1α interaction is involved in the hematopoietic niche.  If 
true, DAG1 expressing osteoblasts may serve as scaffolds enabling the ability of 
NRXN1α, found on HSCs, to mediate between adrenergic and GABAergic signaling found 
in the niche.  This may provide insight into the relationship between the HSC, the MSC, 
the beta-adrenergic neuron and the osteoblasts present in the niche.  Additionally, the 
instructive role NRXN1 plays in GABAergic development may have implications on the 
development of the hematopoietic niche, especially as it applies to the MSC. 
 
NRXN1α axis and disease 
 
In addition to the conditions of schizophrenia and autism, the NRXN1α-axis may be of 
use in treating cancer.  High levels of NXPH expression in myeloid leukemia (Knight, Skol 
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et al. 2009), neuroblastomas (Warnat, Oberthuer et al. 2007), papillary glioneuronal 
tumors (Faria, Miguens et al. 2008), as well as ovarian and breast cancer (Song, Ramus 
et al. 2009) correlates with a poor survival outcome.  In fact, NXPH expression has been 
suggested as a prognostic factor in judging the severity of cancers (Kawasaki, OHIRA et 
al. 2005).  The suppressive effect of recombinant NXPH1 on hematopoiesis may explain 
this correlation. 
 
Our findings show that recombinant NXPH1 is a potent inhibitor of hematopoiesis.  
Neurexophilin secreted by cancers would inhibit HPCs and mature hematopoietic cells 
involved in the immune response.  Because of this, we would expect cancers expressing 
high levels of NXPH to have enhanced immune system suppression and therefore 
evasion.  However, in order for this explanation to work the cancer must not be affected 
by secreted NXPH.  Cancers share many similarities to primitive stem cells, including 
HSCs and our results suggest that HSCs are not affected by NXPH-mediated inhibition.  
This presents the possibility that cancers are similarly not affected by NXPH. 
 
Protection of cancer cells from NXPH-mediated inhibition could occur in two ways: 
either protection via DAG1 similar to HSCs or via downregulation of NRXN1α or other 
proteins downstream of the NXPH-NRXN1α interaction.  The role of DAG1 in cancer 
argues against the former explanation.  In nearly all human cancers analyzed, expression 
of DAG1 is reduced or absent (Cross, Lippitt et al. 2008).  As DAG1 is not available to 
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occupy NRXN1α, it is likely that the advantages of NXPH-expression selects for cancer 
cells that do not express NRXN1α. 
 
The loss DAG1 in cancer presents another way in which proteins involved in this thesis 
may be of clinical relevance.  In addition to noted loss of DAG1 expression in cancer 
cells, restoring DAG1 expression in prostate carcinoma cell lines appears to reduce 
growth and invasiveness of the cancer (Sgambato, Camerini et al. 2007; Sgambato, De 
Paola et al. 2007).  Because the role of DAG1 in cancer appears to involve a change in 
the relationship between the cancerous cell and the ECM, NRXN1α is likely not involved 
as DAG1 preferentially binds normal components of the ECM such as Argin and 
Perlecan.  While beyond the scope of this thesis, further connections between DAG1 
and cancer are of clinical interest. 
 
The inhibitory effect of recombinant NXPH1 on hematopoiesis helps to explain the 
correlation between high NXPH expression in cancers and a negative prognosis.  By 
secreting members of the NXPH family cancers are able to suppress the immune system 
and better evade destruction.  However, in order for this to work cancers must be 
immune to the effect of NXPH.  Because DAG1 is downregulated in most cancers, it is 
unlikely that cancers protect themselves from NXPH-mediated inhibition in the same 
manner as HSCs, rather it seems more likely that NRXN1α or some other factor 
downstream of NRXN1α is downregulated. 
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Members of the NXPH family may also be of interest to HIV research since immune 
system exhaustion is an important difference between HIV infection in humans and SIV 
infection in apes.  One of the critical differences between disease progression of SIV and 
HIV is immune system exhaustion which occurs in the human but not the simian system; 
immune system exhaustion is associated with the onset of AIDS (Pandrea, Sodora et al. 
2008).  This is interesting because during immune system exhaustion in mice, the 
transcription level of NXPH2 is upregulated in macrophages (Rodriguez, Chang et al. 
2004).  Given the suppressive effect of NXPH1 on hematopoiesis, it is reasonable to 
suggest that NXPH family members play a role in immune system exhaustion.  If true, 
inhibiting NXPH may serve to delay the onset of AIDS. 
 
Application of results in the neuronal context 
 
In a neuronal context, DAG1-NRXN1α interaction is mutually reinforcing in development 
of the neuronal synapse (Sugita, Saito et al. 2001).  The hematopoietic system stands in 
contrast to this, where stimulation of DAG1 by recombinant NRXN1α has no effect on 
HPC proliferation. However, consistent with its hypothesized antagonistic role in 
neuropoiesis, NXPH1 acts in an inhibitory manner.  In vitro, NXPH1 specifically inhibits 
proliferation of HPCs stimulated by GM-CSF+SCF when cells are plated in population.  
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However, when progenitor cells are either plated as a single cell in isolation, or in a 
population where DAG1 has been rendered inaccessible through anti-DAG1 blocking 
antibodies, NXPH1 is inhibitory to HPC stimulated by a number of different cytokines, 
alone or in combination.  In addition to identifying a role for NRXN1α signaling in 
hematopoiesis, our results also shed light on the binding of both DAG1 and NXPH1 to 
NRXN1α.  While both DAG1 and NXPH1 bind the second LNS domain of NRXN1α (Lise 
and El-Husseini 2006), they bind different sites within this region.  As the affinity of 
DAG1 varies greatly between different splice variants of NRXN1α (Sheckler, Henry et al. 
2006), the allosteric antagonism of NXPH1 by DAG1 could be modulated without 
affecting NXPH1-binding to NRXN1α.  These may shed further light on this system in 
neuronal system function.  Though DAG1-NRXN1α interaction is implicated in brain 
development and is thought to play a positive role (Michele, Barresi et al. 2002; Satz, 
Ostendorf et al. 2010), the precise function of DAG1 remains unclear (Missler, Zhang et 
al. 2003; Graf, Zhang et al. 2004).  Similar to the hematopoietic system, NXPH1 has been 
associated with an inhibitory role in the neuronal system (Beglopoulos, Montag-Sallaz et 
al. 2005; Zhang, Rohlmann et al. 2005).  It is possible that the function of DAG1 as an 
allosteric inhibitor may resolve some of the controversy surrounding DAG1 function in 
the brain.  If true, these data would further re-affirm the complementary nature of the 
neuropoietic and hematopoietic models.  
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Future directions 
 
The largely descriptive narrative presented within this thesis presents three obvious 
questions for future research: what is going on within the cell during NXPH-mediated 
inhibition, how can this information be used to treat human disease and how does this 
axis relate to the hematopoietic niche?  In the following section, I will attempt to outline 
an approach to study each of these questions. 
 
Mechanism of NRXN1α function in hematopoiesis 
 
The work presented in this thesis offers a descriptive analysis of the relationship 
between NRXN1α, DAG1, and NXPH1: the mechanism of action for NXPH-mediated 
inhibition remains unknown.  As NRXN1α is most commonly associated with voltage-
gated signaling in the brain, any analysis of NRXN1α function should begin there.  
NRXN1α forms a complex with both N- and P/Q-type Ca++ channels (Zhang, Rohlmann et 
al. 2005) as well as Na+/K+ ATPase (Laprise, Lau et al. 2009).  While Ca++ signaling has 
been associated with survival in hematopoiesis (Yang, Tan et al. 2006), Na+ and K+ 
signaling is more promising.  Lithium, an inhibitor of Na+/K+ ATPase activity has been 
shown to specifically stimulate granulopoiesis in response to GM-CSF in vitro (Gallicchio, 
Chen et al. 1983; Gallicchio 1986).  As these studies were performed on cells plated in 
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population, the specific effect of Lithium on cells stimulated by GM-CSF is similar to the 
specific effect of NXPH1 on cells stimulated by GM-CSF+SCF.  Because of this, we 
hypothesize that NXPH1 binds to NRXN1α and activates the Na+/K+ ATPase, thereby 
inhibiting HPC proliferation.  If true, studies with lithium as well as other Na+/K+ ATPase 
inhibitors such as diazepam and propranolol should be able to prevent NXPH1-mediated 
inhibition of HPCs both in vivo and in vitro (Eroglu, Keyer-Uysal et al. 1984). 
 
If Na+/K+ ATPase-inhibitors are unable to prevent NXPH1-mediated inhibition, another 
possible avenue of study involves GABAergic and cholinergic intermediaries.  The effect 
of GABA on hematopoiesis superficially resembles the effect of recombinant NXPH1 on 
hematopoiesis: GABA decreases the cycling status and proliferative potential of HPCs 
(Andang, Hjerling-Leffler et al. 2008).  The failure of conditioned medium from cells 
treated with NXPH1 to inhibit HPC proliferation coupled with the effect of NXPH1 on 
single CD34+ huCB cells argues against this hypothesis.  However, conditioned medium is 
an imprecise tool and firm conclusions, where possible, require a rigor beyond that 
demonstrated in this thesis.  Likewise, studies involving delayed NXPH1 addition to cells 
treated with GM-CSF+SCF in population in vitro (data not shown) which showed some 
inhibition, coupled with the high stability of NXPH1 may allow for secondary effects 
despite the single cell data.  Indeed, an indirect response may explain the ability of 
recombinant NXPH1 to inhibit huCB HPCs: by the time the indirect inhibitory effects of 
recombinant NXPH1 are able to influence huCB HPC proliferation the HPCs have already 
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been induced into cycle by the growth factors present.  Because GABA acts as a 
chemoattractant (Zangiacomi, Balon et al. 2009) and inhibits chemoattracton to SDF1α 
(Seidel, Niggemann et al. 2007), migration studies should reveal whether GABA plays 
any role.  On its own, recombinant NXPH1 does not appear to be chemattractive nor 
does it appear to inhibit chemotaxis towards SDF1α (data not shown).  While these 
studies need to be repeated they argue against the role of GABAergic signaling in NXPH 
function.   
 
Cholinergic signaling is another possibility, though it is not as promising as those 
previously discussed.  Neither nicotine nor acetylcholine have been shown to have an 
effect on HPCs in methylcellulose culture (Koval, Zverkova et al. 2008) which argues 
against the involvement of cholinergic signaling in NXPH1 function; however, these 
studies were conducted on cells plated in a population so DAG1 may obscure the effect.  
Elements in favor of this hypothesis involve α4β2 nicotinic receptor and LT.  NRXN1 is 
involved in the localization of the α4β2 nicotinic receptor in the brain (Cheng, Amici et 
al. 2009), and in the hematopoietic system receptor presence inhibits HPC proliferation 
(Koval, Zverkova et al. 2008).  Additionally, the neuromuscular response to LT is 
cholinergic (Lelyanova, Thomson et al. 2009).  If recombinant NXPH1 were to modulate 
cholinergic function it could explain its inhibition of LT mediated survival, though the 
role of LT as a calcium ionophore is a far more likely mechanism (Ushkaryov, Rohou et 
al. 2008).  The first step to test this hypothesis would be to identify the nature of 
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NXPH1-mediated inhibition of LT induced survival similar to how the relationship 
between DAG1 and NXPH1 was established.  Since both NXPH1 and LT bind the second 
LNS domain of NRXN1α and NXPH1 associates with LT, competitive inhibition is likely.  
Especially considering the independence of LT action and its antagonism by NXPH1 from 
DAG1, it may well be that NXPH1 and LT form a complex which cannot bind the 
hematopoietic NRXN1α splice variant.  If true, pre-incubation of LT and NXPH1 together 
in addition to normal dose-response assays is required.  In order to determine whether 
NXPH1 acts through cholinergic signaling, the first step is to perform an ELISA for 
cholinergic signaling molecules in response to cells treated with anti-DAG1 and 
recombinant NXPH1.  If present, in vivo injection of nicotine as well as α2 and β7 knock-
out mice would be useful tools in determining whether these cholinergic signals play a 
role in NXPH1-mediated inhibition.   
 
Lastly, there are other possibilities presented by Lin2, the protein directly downstream 
of NRXN1α (Hata, Butz et al. 1996; Craig and Kang 2007).  As a member of the MAGUK-
family, Lin2 has a large number of potential binding partners and intersects with many 
different signaling pathways (Anderson 1996).  Any list of proteins interacting with Lin2 
would be incomplete, so it is more expedient to provide several protein domains with 
which Lin2 has been shown to interact: Mint1-interacting CaM kinase, Veli-interacting, 
PDZ, SH3, 4.1-band protein binding, and guanilate kinase (Maximov, Sudhof et al. 1999).  
In the hematopoietic system, over-expression of Lin2 has been shown to inhibit cell 
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growth by blocking cell-cyle progression via Id1 (Qi, Su et al. 2005), which itself has been 
shown to be involved in both lymphopoiesis (Kersten, Dosen et al. 2006) and 
granulopoiesis (Buitenhuis, van Deutekom et al. 2005).  Initial investigation of Lin2 ought 
focus on Id1, using both knock-out and over-expression systems.  If Id1 is not involved in 
recombinant NXPH1-action, high throughput analysis is recommended for investigating 
this system due to the number of possibilities present.  Methods include transposon 
mutagenesis of immortalized hematopoietic cell lines expressing NRXN1α.  Ideally, the 
cell line used would express NRXN1α but not DAG1; if no such line exists one could be 
created by knocking-out DAG1.  This would ensure that DAG1 antagonism of 
recombinant NXPH1 does not interfere with the interpretation of the results. 
 
The role of DAG1 in NXPH-mediated inhibition also needs to be further clarified.  Our 
narrative presents DAG1 as merely an allosteric antagonist; however the evidence for 
our hypothesis is somewhat circumstantial and descriptive. The use of DAG1 blocking 
antibodies in vivo could theoretically be used to support our hypothesis; however DAG1 
plays an important role in muscle function, including cardiac muscle and as such in vivo 
experimentation cannot be recommended.  While DAG1 -/- mice are not viable due to 
absence of mesoderm formation and haploid mice suffer from complications due to 
muscular dystrophies, the role of DAG1 in hematopoiesis could be further clarified using 
embryonic stem cells in a system similar to the one described in work previously 
published from the Broxmeyer laboratory (Ou, Chae et al. 2011).  Additionally, lineage 
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specific knock-out mice could be developed using a Cre-lox system to further investigate 
the role of DAG1 in hematopoiesis.  
 
In addition to the inhibition of HPCs by recombinant NXPH1, the mechanism whereby LT 
promotes HPC survival during growth factor starvation also remains unknown.  In order 
to proceed, first the pro-survival effect of LT must be shown to be anti-apoptotic in 
nature.  A simple annexin V/PI analysis would of growth factor starved cells would 
suffice to demonstrate this.  Provided that a decrease in apoptosis is observed, it is likely 
that calcium influx is responsible.  Calcium influx is likely responsible because in the 
neuronal system LT inserts itself into the cellular membrane and forms a calcium 
ionophore and in the hematopoietic system calcium ionophores have been shown to 
have a pro-survival effect.  Calcium flux in hematopoietic cells has been previously 
examined using pluronic acid (Basu, Ray et al. 2007) and a similar approach could be 
applied here.  However, that particular assay primarily provides information about the 
intracellular release of calcium from the endoplasmic reticulum.  While there is some 
intracellular calcium release in neuronal cells after LT binding, the response is primarily 
from extracellular calcium influx.  Because of these facts, a more ideal mechanism 
would be to use patch-clamp analysis on individually sorted NRXN1α expressing HPCs.  
This technique is how the mechanism of LT was demonstrated in the neuronal system 
and with minimal modifications could theoretically be adapted to hematopoietic cells.  
However, I am unaware of patch-clamp analysis ever having been attempted on 
137 
 
hematopoietic cells so a great deal of optimization may be required before this 
approach yields substantial results.  Patch-clamping is further complicated by the 
heterogeneous nature of phenotypically defined hematopoietic cells so even after 
optimization the results may be difficult to interpret.  Provided that either pluronic acid 
and/or patch-clamping are able to demonstrate that the pro-survival effect of LT on 
HPCs is due to an increase in calcium flux, further investigation would reveal whether 
AKT, CREB, PLC or all three provide the mechanism whereby growth-factor starvation 
induced apoptosis is averted.  
 
However, there is reason to question whether LT works in the same manner in the 
hematopoietic system as in the neuronal system.  The maximal stimulatory dose of LT is 
100 times higher on HPCs than neuronal cells.  Furthermore, a 5nm concentration of LT, 
the lowest concentration at which an effect is observed on HPCs, membrane integrity of 
neuronal cells is completely compromised.  Because NRXN1α has many splice variants 
and splice variants have been shown to affect NRXN1α-ligand interaction, it is probable 
that this difference stems from splice variants in the hematopoietic and neuronal 
system.  This hypothesis could be confirmed by mRNA analysis.  Should this hypothesis 
prove true, microarray analysis would be required to identify potential signaling 
pathways which may be involved.  Depending on which pathways are identified, 
different approaches involving a combination of knock-out mice and various pathway 
inhibitors could be employed to further understand the mechanism of action.  Another 
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possibility is DAG1.  Since all experiments involving LT were performed in a population 
of cells, the presence of DAG1 on other cells in the culture may compete with LT for 
NRXN1α binding. 
 
Another potential area of future research is the interaction between LT and 
Concanavalin A.  In the neuronal system, Concanavalin A binds NRXN1α and, while not 
interfering with LT-NRXN1α binding it does prevent LT insertion into the cellular 
membrane.  The ability of Concanavalin A to inhibit the insertion of LT into the cellular 
membrane is of particular interest if the pro-survival effect of LT is not due to its activity 
as a calcium ionophore.  If the pro-survival effect of LT were still observed in the 
presence of Concanavalin A, the signal would have to be mediated by NRXN1α.  The 
interaction between Concanavalin A and NRXN1α has other potentially interesting 
implications for hematopoiesis as Concanavalin A is a mitogen whose mechanism of 
action has not yet been characterized.  Including Concanavalin A in future in vitro 
experiments, similar to those already performed involving LT and recombinant NXPH1, 
could clarify these questions.     
 
Similar to other areas of overlap between the hematopoietic and neuronal system, the 
differences between them are as illuminating as the similarities.  The difference in 
effective LT dosage between the hematopoietic and neuronal systems suggests that 
different splice variants of NRXN1α are expressed.  The existence of NRXN1α splice 
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variants also presents the possibility that LT cannot bind hematopoietic NRXN1α and 
the pro-survival effect seen is mediated by a different, less sensitive LT receptor, such as 
CIRL.  Further investigation of this system using reagents such as Concanavalin A is 
warranted. 
 
The intracellular mechanisms whereby the observed effects of the NRXN1α-axis are 
mediated remain unknown.  Similar to the initial justification for investigating NRXN1α, 
the function of NRXN1α, DAG1, NXPH and LT in the neuronal system provides a 
framework whereby future research can operate.  Several possibilities present 
themselves for the mechanism of NXPH1-mediated inhibition including voltage-gated 
signaling as well as several different neuronal signaling molecules.  Further clarification 
is also called for in the case of DAG1.  While our data suggests that DAG1 functions 
merely as an allosteric inhibitor of NXPH-mediated inhibition, other interpretations 
remain possible.  As DAG1 knock-out (-/-) mice are not viable, the role of DAG1 in 
hematopoiesis may best be clarified using embryonic stem cells.  The mechanism for the 
toxin LT is slightly more straight-forward due to the pro-survival effect of calcium 
ionophores on HPCs; however the existence of other mechanisms is considered and 
Concanavalin A is presented as a candidate for studying these alternatives.  Should the 
NRXN1α-axis described here prove important in the hematopoietic niche or human 
disease, the mechanisms whereby its members operate will be vital in developing our 
understanding. 
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Clinical applications of the NRXN1α axis. 
 
The involvement of the NRXN1α axis in hematopoiesis may prove to be of clinical 
relevance.  Both schizophrenia and autism involve a disruption of the normal NRXN1α-
axis and this disruption may help explain and treat their hematopoietic phenotypes.  
While these genetic diseases are somewhat rare, cancer and AIDS also potentially 
intersect with the NRXN1α-axis through NXPH.  Of further importance to cancer and 
potentially other hematopoietic diseases, the high concentration of NXPH in umbilical 
CB may have implications for CB transplantation. 
 
The existence of viable human populations deficient in NRXN1α-signaling capacity 
coupled with a recognizable phenotype presents many opportunities for research.  
While murine knock-outs do exist and should be studied, primary human data is of 
greater clinical relevance.  Additionally, the comparison of human and murine knock-out 
systems serves to more fully elucidate the role of the system in hematopoiesis.  As such, 
any discussion of experiments involving knock-out models in vitro should be thought to 
involve both human and murine systems.  Additionally, most of the studies describing 
the hematopoietic phenotypes of schizophrenics and autistics are old and descriptive.  
Re-visiting these systems with modern techniques could reveal a great deal about the 
role of NRXN1 in hematopoiesis.  Furthermore, drugs for the treatment of schizophrenia 
and autism could be rationally designed to target factors downstream of NRXN1α 
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potentially providing a better means of care than those presently in use.  Of particular 
interest would be the repopulating potential of mobilized SRCs from schizophrenics and 
autistics, as it would clarify many questions the data gathered here raises.  The 
proliferative phenotype of schizophrenics and autistics suggests that their cells would 
exhibit a higher degree of contribution per HPC.  Similar to other proliferative systems, 
this may result in exhaustion of the stem cell compartment (Campbell, Basu et al. 2009); 
however, NRXN1α does not appear to be involved in HSC proliferation so exhaustion 
may not occur.  More importantly, the hypothetical role of the NRXN1α-axis in the 
hematopoietic niche (described later) could be observed through sequential serial-
transplantation and homing experiments.   
 
As has been previously noted, the expression level of NXPH correlates with a poor 
prognosis in cancer.  We hypothesize that NXPH secreted by cancers would inhibit HPCs 
and mature hematopoietic cells involve in immune response, which could play a role in 
immune system suppression and evasion by cancer.  Before testing of this hypothesis 
could even begin, primary cancer samples and immortalized cell lines should be 
examined for NXPH expression.  If NXPH family members are expressed in some primary 
cancer samples and cell lines, several candidate cell lines should be identified.  Ideally, 
these cell lines would be paired based on the type of cancer they represent with one 
either expressing or expressing high levels of NXPH and the other either expressing low 
levels or no NXPH.  In each pair, NXPH expression would be silenced in the high 
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expressing sample and overexpressed in the non-expressing member.  The different 
cancer cell lines would then be injected into different groups of mice and the survival of 
mice over time would be examined.  Ideally, mortality would correlate to NXPH levels 
expressed by the cell lines.  If true, experiments involving Freund’s adjuvant and NXPH1 
as cancer therapy would be investigated.  Knock-out mice are also a possibility; however 
they likely possess a pro-inflammatory phenotype that could complicate experimental 
interpretation.   
 
The expression of NXPH also increases during immune system exhaustion.  This is 
interesting because one of the critical differences between disease progression of SIV 
and HIV is immune system exhaustion which occurs in the human but not the simian 
system; immune system exhaustion is associated with the onset of AIDS (Pandrea, 
Sodora et al. 2008).  Given the suppressive effect of NXPH1 on hematopoiesis, it is 
reasonable to suggest that NXPH family members play a role in immune system 
exhaustion.  If true, inhibiting NXPH may serve to delay the onset of AIDS.  Inducing 
immune system exhaustion into NXPH knock-out mice would shed light on this issue.  
Alternatively, anti-NXPH1 antibodies could be used to delay the onset of immune 
system exhaustion in wild-type mice inflected with Leishmania.  If immune system 
exhaustion were delayed, a similar approach for treating HIV patients could be explored. 
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Of particular clinical interest is the relationship between NXPH and huCB.  Unlike 
myelosuppressive chemokines (Lu, Xiao et al. 1993), recombinant NXPH1 is able to 
suppress the colony forming ability of HPCs from freshly isolated huCB.  Additionally, we 
found high concentrations of NXPH-family members in huCB plasma, but not in adult 
human and murine peripheral blood.  Taken together, these findings may be of some 
meaning in the context of huCB transplantation.  While offering many advantages as 
compared to other sources of HSCs, reconstitution time is longer in patients who have 
received huCB transplants.  It is possible, but not yet determined that members of the 
NXPH-family may play a role in the engraftment time of huCB cells in a clinical context.  
To test this hypothesis, huCB cells will be resuspended in sterile filtered huCB plasma, 
FBS, and FBS augmented with varying concentrations of NXPH1 and different 
concentrations will be injected into sublethally irradiated NOD/SCID mice.  To control 
for the long reconstitution time being an intrinsic property of huCB HSCs, the 
experiment will be performed in tandem with muBM cells.  Limiting dilutions of C57Bl/6 
competitor cells will be injected and the effect of NXPH on repopulation will be 
examined.  
 
The function of NXPH in huCB remains mysterious.  Given the suppressive effects of 
NXPH on HPC proliferation, it is possible that NXPH is present to inhibit the 
development of more mature cells in huCB, thereby maintaining an environment more 
conducive to HSC maintenance.  Indeed, this hypothesis is supported by the fact that 
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the population of hematopoietic cells in huCB is considered relatively naïve.  Because 
the huCB environment is conducive to HS/PC maintenance, huCB is able to be stored at 
room temperature for long periods of time with minimal impact on the colony-forming 
potential of HPCs (Broxmeyer, Douglas et al. 1989).  If NXPH contributes to the 
environment which supports this maintenance, exposing huCB samples to anti-NXPH1 
antibodies would lead to faster HPC degradation.  Another, more powerful, study would 
be to examine the potential of HS/PCs derived from the placentae of NXPH knock-out 
mice, provided pilot studies demonstrated that NXPH is present in murine placentae.  
Double knock-outs for NXPH1 and 3 exist, though evidence suggests that it is NXPH2 
that is expressed in the murine hematopoietic system so a triple knock-out would need 
to be developed.  If NXPH is involved in HS/PC maintenance we would expect a decrease 
in the absolute number and quality of HS/PCs in the knock-out.  A third study would be 
to expand huCB CD34+ cells in the presence of NXPH1 in FBS as well as in huCB plasma 
with its NXPH depleted via A/G agarose and examine the SRCs in NOD/SCID mice.  While 
NXPH1 does not affect the in vitro performance of expanded CD34+ cells, if NXPH helps 
to maintain stemness in vitro assays would be unable to detect it. 
 
While much work remains to be done, the work presented here creates a foundation for 
future clinical work.  The NRXN1α-axis is involved in schizophrenia, autism, cancer and 
HIV.  Additionally, the presence of NXPH in huCB may be of relevance to huCB 
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transplantation as well as HSC maintenance.  Further study of the proteins characterized 
here may yield new treatments for disease as well as new transplantation techniques.     
 
The NRXN1α-axis and the hematopoietic niche 
 
An interesting finding was DAG1 expression in the bone marrow.  While DAG1 appears 
to be expressed on many cells in the bone marrow, histology reveals that it is most 
heavily expressed in osteoblasts.  The co-localization of DAG1 and NRXN1α in the BM 
observed together with the physiological response of hematopoietic cells to 
recombinant NXPH1 exposure leads us to hypothesize that primitive HSCs are bound to 
DAG1 in the niche.  The presence of NRXN1α on the HSC in the niche has interesting 
implications for both niche function and development. 
 
We hypothesize that NRXN1α expressed on the HSC is able to mediate between 
GABAergic signaling from the MSC and adrenergic signaling from the beta-adrenergic 
neuron in the niche.  A variety of different avenues exist for studying this system to 
determine if it is true.  The most direct route would be to thaw the NRXN1α -/- as well 
as NRXN1 -/- mouse embryos and examine their hematopoietic system, especially in 
response to GABAergic and adrenergic compounds.  While only NRXN1 expression has 
been observed at the RNA level in hematopoietic cells, due to complementation it may 
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be prudent to examine triple knock-outs eliminating the entire NRXN family, though 
developmental problems complicate this study.  Another avenue is analysis of CD34+ 
CD38- huCB populations.  FACS analysis of NRXN1α and DAG1 expression of CD34+ CD38- 
huCB cells suggests that two separate populations of cells exist.  Both populations 
express NRXN1α and DAG1; however the brightness of the two proteins is different.  In 
one population, NRXN1α is very bright whereas DAG1 is dim; whereas in the other 
population DAG1 is bright and NRXN1α is dim.  While these populations express similar 
levels of other stem cell markers and do not differ in their ex vivo proliferation, in vivo 
analysis is required to truly assay stem cell function.  Based on our results in the mouse 
system in vivo, one might expect the NRXN1α dim population to describe the more 
primitive population; however such thinking may be premature due to the role of 
NRXN1α in synaptogenesis.  In the neuronal system, NRXN1α serves an instructive role 
in GABAergic development.  Taken together with the fact that the adult hematopoietic 
niche is not the site of development for HSCs and the resemblance of MSCs to post-
synaptic GABAergic neurons, it is possible that the adult hematopoietic niche is created 
through a process similar to GABAergic synaptic development.  If true, that one would 
expect the population with the higher expression level of NRXN1α to contain either 
more or better SRCs.  Because huCB transplant involves relatively little GVHD, it would 
be possible to test this hypothesis by a sex-mismatched competitive repopulation assay.  
If this hypothesis were to demonstrate some promise, the next step would be to shift 
the system over to a model more conducive to developmental studies, such as 
zebrafish.  
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Conclusion 
 
Similarities between mammalian tissues represent a powerful tool for directing 
experimental discovery (Terskikh, Easterday et al. 2001).  Here we have demonstrated 
that three previously identified elements of the neuronal system, DAG1, NRXN1α and 
NXPH1, and perhaps other members of the NXPH-family, are present and functional 
within the hematopoietic system and form a tightly regulated axis.  DAG1 appears to 
bind NRXN1α and protect HPCs from NXPH1 binding and subsequent inhibition.  In vivo 
this protection is observed on phenotypically defined LTR-HSCs, suggesting that the 
DAG1-NRXN1α axis may play a significant role in the hematopoietic niche.  In addition to 
their scientific value, these results have a variety of potential clinical implications.  The 
high concentrations of NXPH present in huCB may at least partially be involved in the 
time to engraftment for CB transplants, while high NXPH expression, which correlates 
with a negative in cancer, may be involved in immune system evasion by cancer.  
Further studies in this area are of future experimental and clinical interest. 
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